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ABSTRACT OF DISSERTATION

OPIOID-CANNABINOID CODRUGS WITH ENHANCED ANALGESIC AND
PHARMACOKINETIC PROFILE

The central hypothesis of the dissertation is that “the design and synthesis of a codrug of
an opiate and a cannabinoid can be achieved which is stable in the gastrointestinal tract
and shows a superior pharmacological and pharmacokinetic profile when compared to a
physical mixture of the two parent drugs.” To prove the hypothesis, a series of novel
codrugs were prepared by conjugation of the opiate drug codeine with ∆9tetrahydrocannabinol (∆9-THC), cannabidiol, abn-cannabidiol and an opiate prodrug 3-Oacetylmorphine with ∆9-THC. Codeine-cannabinoid codrugs were evaluated for analgesic
activity in the rat after oral administration. The Cod-THC codrug showed greater
effectiveness as well as prolonged pain management properties as compared to the parent
drugs. The stability of Cod-THC codrug in aqueous solutions from pH 1-9, in simulated
gastrointestinal fluids, in brain homogenate and the hydrolysis of the carbonate ester
linkage in rat plasma suggested that after oral administration, the codrug would be
absorbed intact from the GI tract and then hydrolyze in the plasma to generate both
parent drugs. The enzymes present in rat brain homogenate were incapable of cleaving
the codrug into the parent drugs.
The pharmacokinetic profiles of the Cod-THC codrug and an equimolar physical mixture
of the parent drugs were evaluated in rats. The plasma concentrations of codeine and∆

9

-

THC were much higher after codrug administration compared to the plasma
concentrations of these drugs after oral administration of an equimolar physical mixture.
The parent drugs were also present in the plasma for longer period of time compared to

the physical mixture, probably due to the sustained release of the parent drugs from
codrug in the plasma. The concentrations of codeine and Δ9-THC were much higher in rat
brain after oral administration of the Cod-THC codrug as compared to brain
concentrations of these drugs after oral administration of the physical mixture. Thus, the
design and synthesis of an opiate and a cannabinoid codrug was achieved which was
stable in the gastrointestinal tract, showed enhanced analgesic effects as compared to the
parent drugs, and also showed a superior pharmacokinetic profile when compared to a
physical mixture or the two parent drugs.
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Chapter 1
Object of the Study and Literature Review
1.1 Hypothesis

The hypothesis to be tested in this dissertation work is as follows: the design and
synthesis of a codrug comprising an opiate drug and a cannabinoid drug can be achieved
which is stable in the gastrointestinal tract, and exhibits a superior pharmacological and
pharmacokinetic profile when compared to an equimolar physical mixture of the two
parent drugs.

1.2 Overall Aim

There is a continuing need for analgesic medications that are able to provide high
efficacy pain relief while providing more favorable pharmacokinetics and reducing the
possibility of undesirable side effects. Enhancement of the analgesic effect of opioids by
combination with cannabinoids has been previously described (Cichewicz et al., 1999).
These opioid and cannabinoid drugs target opioid and cannabinoid receptors, which are
found throughout the central and peripheral nervous system (Cichewicz et al., 1999;
Cichewicz and McCarthy, 2002). In addition, these two classes of drugs produce similar
effects on calcium levels and cyclic AMP accumulation through G protein-mediated
pathways (Bloom and Dewey, 1978). However, appropriate dosing of these active agents
to deliver the drug(s) to the site of action, e.g., the brain or spinal column, can be difficult
because of their differential pharmacokinetics. Therefore, there is a need to devise a way
of administering opioids and cannabinoids concomitantly to provide a more favorable
pharmacokinetic profile for optimizing the enhancement of the analgesic effects.

1

1.3 Methodology to be Utilized in this Study
•

To synthesize codrugs comprising one opioid molecule, and one cannabinoid
molecule, both covalently bound via a linker that is capable of cleaving to the
parent drugs in the body.

The two drugs will be connected by means of a

cleavable covalent linker (e.g. ester, carbonate, amide, carbamate, etc.), which
should hydrolyze in vivo to generate the active parent drug entities.
•

To evaluate the chemical and enzymatic stabilities of one of the codrugs, in order
to determine its stability to hydrolysis in aqueous media over a range of pHs, and
its stability in simulated gastric and intestinal fluids, rat plasma, and rat brain,
utilizing a stability-indicating HPLC-UV assay.

•

To provide a codrug with improved drug stability, as well as improved targeting
of parent drugs to the site of action (central nervous system) as compared to a
physical mixture of the parent drugs.

•

To provide a codrug with more desirable pharmacokinetic properties, in particular
for drugs with different physicochemical properties (e.g. differences in lipid
solubility, water solubility, polarity, etc.). To determine rat plasma and brain
concentrations of codrug and parent drugs after oral administration of one of the
codrugs. To determine the bioavailability of the codrug, and to compare these
properties with those of a physical mixture of the parent drugs after oral and iv
administration, utilizing an LC-MS/MS analytical methodology.

•

To provide a codrug that has the potential for treating patients in pain with an
opioid analgesic, that affords prolonged and effective pain management, while at
the same time providing the opportunity to reduce the side effects, dependence,
and tolerance that patients usually experience when subjected to prolonged
treatment with opioids.

•

To provide a codrug which, after oral administration, produces a superior
analgesic response to pain (acute, chronic and/or cancer-related) as compared to
the response from a physical mixture of the two parent drugs.

2

1.4 Literature Review

1.4.1 Codrugs/Hybrid Drugs

There are instances in prodrug design where the prodrug molecule incorporates
two identical or non-identical drugs into a single chemical entity. This is often desirable
when two synergistic drugs have different physicochemical and pharmacokinetic
properties, and it is desirous to have the parent drugs released concomitantly at the site of
action to obtain a synergistic pharmacodynamic effect that is not attainable by delivering
a physical mixture of the two drugs. Also, one of the drugs in the codrug structure may be
incorporated to counterbalance the known side-effects associated with the other parent
drug, or may amplify the pharmacodynamic effect of the other parent drug through an
action at another biological target. Thus, codrugs can be designed to overcome various
barriers to drug formulation and delivery, such as poor aqueous solubility, chemical
instability, insufficient oral absorption, rapid pre-systemic metabolism, inadequate brain
penetration, toxicity and local irritation. Structurally, a codrug (also known as a mutual
prodrug, or hybrid drug) comprises two or more different drugs within a single chemical
entity where the drugs must each contain an appropriate chemical functionality to enable
them to be connected together, either directly or by means of a cleavable, biolabile
covalent linker (Hamad et al., 2006). Such codrugs can be either bipartate or tripartate in
nature (Silverman, 2004) (Fig.1.1).

Thus, a codrug strategy can be useful when:

•

Synergistic drugs need to be given concomitantly to act at the same time, either at
the same or different biological targets.

•

The physicochemical properties of two synergistic drugs are not favorable for
delivery of the two drugs as a physical mixture, but can be improved by chemical
combination of the two drugs.

3

•

Improved pharmacokinetics results from a chemical combination of two
synergistic drugs compared to those of a physical mixture of the two drugs.

As with prodrugs, the codrug structure can incorporate two drugs joined together
by linker moieties such as ester, carbonate, amide, carbamate, etc., which are then
cleaved enzymatically in vivo to release the active drugs at a required site in the body. By
appropriate structural design of these linkers, it may be possible to control the release
kinetics of one or both drugs. When the two drugs are chemically combined together, the
resulting codrug will usually have different physicochemical properties to those of the
individual parent drugs, which may provide superior properties for delivery of the two
drugs when compared to delivery of a physical mixture of the drugs (Howard et al.,
2007).

O

O
DRUG-1

O

C

DRUG-2

DRUG-1

(A)

O

C

O

DRUG-2

(B)

Fig. 1.1 Examples of bipartate and tripartate codrugs: A) conjugation of a carboxylic drug
with an alcoholic drug to form a bipartate codrug where the two drugs are connected by
an ester linkage which cleaves in vivo to release only the two parent drugs; B)
conjugation of two alcoholic drug molecules via a carbonate ester linker to form a
tripartate codrug which cleaves in vivo to form the two parent drugs and an equivalent of
carbonic acid.

An ideal codrug will generate the parent drugs with high recovery rates, and will
incorporate linkers that give rise to non-toxic linker residues upon in vivo cleavage. There
may be other advantages in delivering of two drugs as a single chemical entity versus a
physical mixture. These include, for example, improved chemical stability of the
formulation (i.e. no chemical interaction of the two parent drugs within the formulation),
improved metabolic stability (especially with regard to possible protection of either drug
from high first pass metabolism), as well as improved targeting of drugs to the site of
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action (e.g., the central nervous system), and more desirable pharmacokinetic properties,
in particular for drugs with different physicochemical properties (e.g., differences in lipid
solubility or polarity).

There are also certain disadvantages that are associated with a codrug strategy.
One disadvantage is that codrugs are usually large molecules with molecular weights that
are often greater than 500. Thus codrugs with large molecular weights may well violate
Lipinsky’s rule of five (Lipinski et al., 2001) as favorable molecules for oral or topical
dosage form development, or for CNS delivery. In addition, by the very nature of their
structural design, these cleavable molecules may possess poor stability profiles for
formulation development. Thus, it must be initially established that the codrug is resilient
enough to withstand the rigors of formulation development, but must not be too stable
that it will not efficiently cleave to the parent drugs in vivo.

Another important aspect of codrug design is the toxicological significance of
delivering a codrug to an individual. Since codrugs are novel chemical entities (although
the parent drugs they generate may or may not be novel), they will have to be treated as
new xenobiotics by the FDA, as are all new drugs entities that have never been
previously administered to humans. Thus, there are important toxicological and safety
issues associated with the development of codrugs as they move toward clinical status.

Several important criteria are required for codrugs to be effective. The codrug
must be well absorbed and distribution, metabolism and elimination of the codrug should
be superior to the physical mixture of the parent drugs. Both parent drugs should be
released concomitantly and quantitatively after absorption, and the maximal effect of the
drug combination should occur when a simple molar ratio, i.e. 1:1, 2:1, or 3:1, is utilized.

Before designing the codrug, one needs to know the route of administration.
Routes of administration can be broadly divided into topical, enteral and parenteral
routes. The topical route has a local drug effect. The drug is directly applied where the
action is desired, e.g. asthma medications, eye or eardrops, and decongestant nasal
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sprays. In the enteral route, drug administration involves any part of the gastrointestinal
tract. The effect is non-local. Sublingual, oral and rectal are all enteral routes. In
sublingual administration, the drug is placed under the tongue, is rapidly absorbed and
avoids first-pass metabolism. The first-pass effect term refers to the hepatic metabolism
of a drug when it is absorbed from the gastrointestinal tract and delivered to the liver via
the hepatic portal circulation. The greater the first-pass effect, the lower the concentration
of drug that reaches the systemic circulation. In the oral (p.o., per os) route, the drug is
swallowed. It passes through the whole gastrointestinal tract. Drugs taken orally are
usually cheaper than ones administered by any other route, and can easily be selfadministered (minimal invasiveness) by the patient. The disadvantage of oral delivery is
that the drug has to be absorbed from the gastrointestinal tract and go through the first
pass effect. Sometimes this route of administration is inefficient because only part of the
drug may be absorbed; also a significant first-pass effect may occur. In addition, some
orally administered drugs can cause irritation of the gastric mucosa, and cause nausea and
vomiting.

The different parenteral routes for drug administration are intravenous,
intraarterial, intramuscular and subcutaneous, and more rarely, intracerebral (i.e. directly
into the brain), intraosseous (into the bone marrow), or intradermal (into the skin itself).
These different parenteral routes are depicted in Fig. 1.2 (Copeland, 2009).

Fig. 1.2 Parenteral routes of drug administration (Copeland, 2009)
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Times taken by drugs to show effect in different routes of administration are
given below:

•

intravenous 30-60 seconds

•

inhalation 2-3 minutes

•

sublingual 3-5 minutes

•

intramuscular 10-20 minutes

•

subcutaneous 15-30 minutes

•

rectal 5-30 minutes

•

ingestion 30-90 minutes

Note: drugs given orally take more time than any other route to show a
pharmacological response, but the oral route is considered to be the safest, pain free and
cheapest method of drug administration. Other routes are used if there is an emergency
situation where the effect of the drug is needed in seconds (Silverman, 2004).

Several important criteria are required for codrugs to be effective as compared to
a physical mixture of the parent drugs, or either of the parent drugs alone. The codrug
must be well absorbed. When a drug enters the body, it encounters a wide range of pHs.
A drug given orally faces low pHs in the range 1-2 in the stomach, pHs around 4-6 in the
intestine, and pHs in the range 5-9 in the colon. These pH values vary in the body,
depending on the presence of an empty stomach or a fed stomach. The pH values
generally increase after food is ingested. For example, if the pH of the empty stomach is
around 1-2, then after the food is taken, it will increase to around 2.5-4. If a codrug can
survive in this pH range and reach the plasma without being hydrolyzed, it can reach the
plasma intact, and with appropriate design can release the parent drugs after hydrolysis
by plasma enzymes. The codrug will also be exposed to various enzymes in the
gastrointestinal tract which may hydrolyze the codrug to release the parent drugs before
the codrug reaches the systemic circulation. Therefore, important insights can be obtained
from incubating the codrug with simulated gastrointestinal fluids in in vivo stability
7

studies before carrying out more expensive and time-consuming in vivo pharmacokinetic
studies. These include stability in simulated gastric fluid (SGF) and simulated intestinal
fluid (SIF). These fluids are specified in the United States Pharmacopeia (USP). The SGF
components are pepsin (an acidic protease) and NaCl, and the pH is adjusted to 1.2 with
HCl. SGF simulates stomach fluid and incorporates both acidic and enzymatic hydrolysis
conditions. The SIF components are pancreatin (a mixture of amylase, lipase and protease
from hog pancreas) in monobasic phosphate buffer and the pH is adjusted to 6.8 with
NaOH. SIF mimics the pH and hydrolytic enzymes in the intestine. The main purpose of
these stability studies is to predict stability of the codrug after oral dosing. The codrug’s
stability in these two fluids can often be a guide on how to structurally modify the codrug
to improve gastrointestinal stability. This information helps in optimizing codrug
bioavailability and prioritization of compounds for subsequent in vivo pharmacokinetic
studies.

Once the drug reaches the systemic circulation, it encounters a large number of
hydrolytic enzymes, such as cholinesterase, aldolase, lipase, dehydropeptidase, and
alkaline and acid phosphatase in the blood. If the drug has affinity for one of these
enzymes and it has the correct hydrolysable group in an appropriate position in the
molecule, it can be degraded in the plasma to generate the parent drugs. In a codrug
strategy, in vitro plasma stability studies are important and help identify a codrug with
the optimal properties for releasing the active parent drugs after absorption from the g.i.
tract. Therefore, it is very important to carry out the in vitro plasma stability studies
before embarking on the in vivo pharmacokinetic study. This will ensure that compounds
are subsequently investigated in vivo that are most likely to be successful therapeutics
(Kern and Di, 2008).

Also, both conjugated drugs should be released concomitantly and quantitatively
after absorption from the gastrointestinal tract. The maximal effect of the combination of
the two drugs should occur at a simple ratio, i.e. 1:1, 2:1, or 3:1, and the distribution and
elimination of the codrug should be superior to the physical mixture of the parent drugs
(Cynkowska et al., 2005).
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The codrug can exert its action in two different ways. One way is absorption from
the gastrointestinal tract into the systemic circulation as a single chemical entity followed
by cleavage in the plasma and release of the two parent drugs. The other way is to reach
the site of action first, e.g. the brain, and then undergo cleavage to the parent drugs via
the action of site-specific enzymes present in the target tissue. With regard to brain
delivery, small codrug molecules with high lipid solubility and a low molecular mass of
less than 400–500 Daltons will cross the blood-brain barrier (Pardrige, 2001), and such
codrugs can be designed to contain a linker that can be cleaved specifically by brain
enzymes. Alternatively, a codrug can be designed in such a way (i.e. molecular weight
exceeding 500) that it will not be able to cross the blood-brain barrier, but can deliver the
parent drugs to the brain after release from the codrug in the plasma.

1.4.2 Marketed Codrug

A good example of an effective and marketed codrug is the antibiotic sultamicillin
(Unasyn Oral), a tripartate codrug of ampicillin and penicillanic acid sulfone (Fig. 1.3)
(Baltzer et al., 1980; Hartley and Wise, 1982). Ampicillin is a well-known β-lactam
antibiotic, but suffers from ineffectiveness against resistant bacteria that excrete high
concentrations of the bacterial enzyme, β-lactamase. β-Lactamase degrades penicillins
such as ampicillin by hydrolysis of the β-lactam ring with consequent loss of antibacterial
activity. Subsequent co-administration of a β-lactam antibiotic with a β-lactamase
inhibitor was utilized as a strategy for treating resistant strains of bacteria. For example,
the antibiotic Augmentin is a mixture of the β-lactam penicillin, amoxicillin and the βlactamase inhibitor, potassium clavulinate (Fig. 1.3). One of the problems of
administering the two synergistic drugs together (as a physical mixture) is that they may
not have similar pharmacokinetic profiles, and thus may not arrive at the target site at the
same time or at the same concentration. The codrug sultamicillin incorporates a labile
linker, which on hydrolysis by a plasma esterase affords the two synergistic parent drugs
in equimolar amounts together with a molar equivalent of formaldehyde.
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Fig.1.3 Sultamicillin codrug and the in vivo hydrolysis products generated from the
codrug (Baltzer et al., 1980; Hartley and Wise, 1982).

1.4.3 Codrug for the Treatment of Proliferative Diabetic Retinopathy

The codrug strategy has previously been utilized when the physicochemical
and/or pharmacokinetic properties of two synergistic drugs are not favorable for delivery
of the two drugs as a physical mixture, but can be improved by chemical combination of
the two drugs. For example, 5-fluorouracil (5-FU) is a polar, water-soluble antiviral and
cytotoxic drug that is rapidly cleared from the vitreous when delivered topically to the
eye. In a topical drug combination treatment consisting of 5-FU and the lipophilic, waterinsoluble, anti-inflammatory drug, trihydroxy steroid (THS), a codrug strategy was
utilized which provided a superior sustained release delivery of the two synergistic parent
drugs for the treatment of diabetic retinopathy (Howard et al., 2005). The individual
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physicochemical properties of 5-FU and THS are not favorable for sustained release of a
physical mixture of the two drugs. However, utilizing a codrug approach, the chemical
combination of 5FU and THS in a 2:1 molar ratio, respectively (for optimal synergistic
activity) afforded a molecule with greatly improved physicochemical characteristics for
sustained delivery compared to formulations of the two drugs as a physical mixture
(Howard et al., 2005). Fig. 1.4 shows the structure of THS, 5-FU and the THS-BIS-5-FU
codrug. THS was synthesized from Reichstein’s substance S as depicted in Scheme 1.1.
The 5-FU-THS codrug was synthesized via the intermediacy of a chloroformate
analogue, as shown in Scheme 1.1 (a) and 1.1 (b).
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Fig. 1.4 Structures of THS, 5FU and the THS-BIS-5FU codrug
(Reprinted from Journal of Enzyme Inhibition and Medicinal Chemistry, Howard et al.,
2005, copyrighted by Informa Healthcare, used by permission”)
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Scheme 1.1: (a) Synthesis of the chloroformate analogue of THS
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Enzyme Inhibition and Medicinal Chemistry, Howard et al., 2005, copyrighted by
Informa Healthcare, used by permission”)
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Fig. 1.6 Cumulative release of THS and 5FU from neat pellets containing 2 mg of the
THS-BIS-5FU codrug in bovine vitreous humor (Reprinted from Journal of Enzyme
Inhibition and Medicinal Chemistry, Howard et al., 2005, copyrighted by Informa
Healthcare, used by permission)
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The 5-FU-THS codrug was designed as a “chemical delivery” system (Howard et
al., 2005) which joined together the two drugs via a labile linker moiety. The
physicochemical properties of the codrug were favorable for both formulation as a
sutured ophthalmic pellet, and for slow dissolution of the codrug pellet in the vitreous
humor. The labile linker was specifically designed to undergo rapid hydrolysis once the
codrug pellet had dissolved, providing sustained release of the parent drugs, which was
dependent on the rate of dissolution of the codrug pellet. Fig. 1.5 illustrates the hydrolytic
behavior of the codrug. According to the figure, one molar equivalent of the codrug
produces one molar equivalent of THS, two molar equivalents of 5FU, and two molar
equivalents of both formaldehyde and carbon dioxide. Another important consideration in
the design of the 5-FU-THS codrug was the structure of the labile linker. The two drugs
were linked together via a linker that afforded hydrolysis products that were considered
to be non-toxic. The pellets containing the THS-BIS-5FU codrug simultaneously released
THS and 5FU in 0.1 M phosphate buffer, (pH=7.4), human serum and in bovine vitreous
humor. Fig. 1.6 depicts the release of THS and 5FU from the codrug in bovine vitreous
humor. The results demonstrate that a neat pelleted THS-5FU codrug can be utilized as a
sustained release ocular delivery form of the parent compounds, and that the unique
physicochemical properties of the codrug allow both a slow dissolution and a rapid
release of the two parent drugs (Fig. 1.6).

1.4.4 Codrug for the Simultaneous Treatment of Alcohol Abuse and Tobacco
Dependence

Naltrexone (NTX) is a useful drug for the treatment of alcohol abuse (Volpicelli
et al., 1992), and cigarette smoking is known to be a social cue for alcoholics. Thus,
many alcoholics are also chronic smokers. Naltrexol (NTXOL) is the active metabolite of
NTX (Rukstalis et al., 2000; Wang et al., 2001). NTX produces severe gastrointestinal
effects, has low bioavailability, and is a hepatotoxin. Also, poor patient compliance via
the oral route is observed, and neither NTX nor NTXOL is deliverable in therapeutic
concentrations via the transdermal route (Kiptoo et al., 2006). A codrug approach was
applied to attempt to solve these problems. Hydroxybupropion (BUPOH) is the active
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metabolite of the orally active smoking cessation agent, bupropion (Zyban) (Cooper et
al., 1994; Ascher et al., 1995; Sanchez and Hyttel 1999, Slemmer et al., 2000). A
transdermal NTX-BUPOH or CB-NTXOL-BUPOH codrug should have improved
transdermal delivery characteristics, lower toxicity, and afford better patient compliance
than either NTX or NTXOL. This single codrug entity has the potential to treat both
alcohol and nicotine abusers when delivered transdermally. Fig. 1.7 shows the structure
of NTX, NTXOL, BUP, BUPOH and the two codrugs of BUPOH covalently linked to
either NTX or NTXOL.
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Scheme 1.2: Syntheses of NTX-BUPOH and CB-NTXOL-BUPOH codrugs humor
(Reprinted from Journal of Bioorganic and Medicinal Chemistry Hamad et al., 2006,
copyrighted by Elsevier, used by permission)
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The syntheses of the two codrugs were achieved by initial formation of a
chloroformate derivative of BUPOH followed by coupling of this intermediate with NTX
and NTXOL. The step-wise syntheses of the codrugs are shown in scheme 1.2 (Hamad et
al., 2006).

In order to determine the stability of the codrugs, hydrolytic studies were carried
out in isotonic phosphate buffer at pH 7.4 (physiological pH). The results showed that the
codrugs were susceptible to hydrolysis and produced the parent drugs at physiological
pH. Table 1.1 summarizes the results of hydrolytic study performed on the two
synthesized codrugs and the parent drugs. The proposed hydrolytic conversion of the
NTX-BUPOH codrug to the parent drugs is shown in detail in Fig. 1.8. The NTXBUPOH codrug undergoes cleavage of the carbonate bond to generate NTX, and a stable
cyclic carbamate intermediate of BUPOH, which then undergoes hydrolysis to
subsequently generate BUPOH. The chemical stability of the NTX-BUPOH codrug was
studied in isotonic phosphate buffer at pH 7.4 over 4 days. The disappearance of the
codrug and the appearance of the two parent drugs over time are shown in Fig. 1.9. The
rate of appearance of NTX was identical to the rate of disappearance of the codrug. On
the other hand, the rate of formation of BUPOH was found to be slower than the rate of
disappearance of the codrug, involving the formation of a relatively stable intermediate.
That intermediate was identified as the 5-membered cyclic carbamate analogue of
BUPOH (Hamad et al., 2006).

The stability of the carbonate codrug of 6-β-naltrexol and hydroxubupropion was
also evaluated in Guinea pig plasma after transdermal delivery. Fig. 1.10 illustrates the
hydrolytic profile of the carbonate codrug (CB-NTXOL-BUPOH) and the time course of
formation of the two active parent drugs in the plasma. The release of 6-β-naltrexol from
the codrug was a one-step process, as confirmed by rate of appearance of 6-β-naltrexol
being the same as the rate of disappearance of the carbonate codrug. The release of
BUPOH involved the initial formation of the cyclic carbamate analogue of BUPOH,
which was then converted subsequently to the parent drug, BUPOH. The rate of
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hydrolysis of the CB-NTXOL-BUPOH codrug in plasma was 3 times faster compared to
the rate of hydrolysis in isotonic phosphate buffer at pH 7.4 (Kiptoo et al., 2008).

The

CB-NTXOL-BUPOH

codrug

and

6-β-naltrexol were

administered

transdermally to hairless Guinea pigs and the concentrations of the parent drugs in the
plasma were determined by LC-MS/MS. The plasma concentration profile of the analytes
following topical application of either CB-NTXOL-BUPOH or 6-β-naltrexol is shown in
Fig. 1.11. The results showed a fivefold enhancement in the transdermal delivery of 6-βnaltrexol when given in the form of the codrug. Also, the codrug delivered a significant
amount of BUPOH to the plasma when administered transdermally. The cyclic carbonate
intermediate of BUPOH was not detected in the plasma of codrug-treated Guinea pigs.
The calculated pharmacokinetic parameters for the CB-NTXOL-BUPOH codrug and 6-βnaltrexol are listed in Table 1.2 (Kiptoo et al., 2008).

Table 1.1 Physicochemical Properties of NTX (1), NTXOL(2), BUPOH(4) and the
carbonate codrugs, NTX-BUPOH (25) and CB-NTXOL-BUPOH (26)

(Reprinted from Journal of Bioorganic and Medicinal Chemistry Hamad et al., 2006,
copyrighted by Elsevier, used by permission)
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Fig 1.9 Hydrolytic profile of the carbonate drug hybrid, NTX-BUPOH, in isotonic
phosphate buffer at pH 7.4 (Reprinted from Journal of Bioorganic and Medicinal
Chemistry Hamad et al., 2006, copyrighted by Elsevier, used by permission)

Table 1.2 Pharmacokinetic parameters of NTXOL in the Guinea pig after application of a
gel formulation containing either CB-NTXOL-BUPOH or NTXOL base. (Reprinted from
European Journal of Pharmaceutical Sciences, Kiptoo et al., 2008, copyrighted by
Elsevier, used by permission)
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Fig 1.10 Hydrolytic profile of the carbonate drug hybrid, CB-NTXOL-BUPOH, in
Guinea Pig Plasma at 37oC (Reprinted from European Journal of Pharmaceutical
Sciences, Kiptoo et al., 2008, copyrighted by Elsevier, used by permission)

Fig 1.11 Mean (±S.D.) plasma concentration profiles in guinea pigs after topical
application of a gel formulation containing either CB-NTXOL-BUPOH or 6-β-Naltrexol
(control). The dotted line (----) indicates the plasma concentration after the removal of the
formulation. . (Reprinted from European Journal of Pharmaceutical Sciences, Kiptoo et
al., 2008, copyrighted by Elsevier, used by permission)
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1.4.5 L-DOPA Codrugs

Dopamine is deficient in the brains of patients suffering from Parkinson’s disease.
Unfortunately, dopamine cannot be given as a drug for this disease because it cannot
cross the blood-brain barrier. L-Dopa is a precursor of dopamine, and is used in the
treatment of Parkinson’s disease. L-Dopa crosses the blood-brain barrier via facilitated
transport, and is then converted to dopamine in the brain by the enzyme DOPA
decarboxylase. For the treatment of Parkinson’s disease, L-Dopa is given in combination
with a peripheral dopa decarboxylase inhibitor such as carbidopa, to prevent degradation
of L-Dopa in the systemic circulation. Entacapone is another L-Dopa decarboxylase
inhibitor, which is currently used with L-Dopa to treat Parkinson patients. Since oral LDopa bioavailability is low, a codrug approach was utilized, by combining L-Dopa and
entacapone via an ester linkage to improve L-Dopa brain delivery (Fig.1.12). The codrug
showed stability in aqueous media at different pHs and was hydrolysed to the parent
drugs in liver homogenate, fulfilling the codrug criteria (Leppanen et al., 2002).
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Fig.1.12 L-Dopa ester of entacapone

A series of codrugs have also been designed by linking L-Dopa and dopamine
with antioxidant compounds such as α-lipoic acid, glutathione, caffeic acid, carnosine,
benserazide and N-acetylcysteine (Stefano et al., 2006 [1]; Stefano et al., 2007; Piera et
al., 2008; Stefano et al., 2006 [2]; Pinnen et al., 2009).
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As shown in Fig.1.13, L-Dopa and dopamine can be linked to α-lipoic acid and
glutathione via an amide linkage (Stefano et al., 2006). α-Lipoic acid is an effective
antioxidant. It exists as dihydrolipoate in vivo, which can regenerate (reduce) antioxidants
such as glutathione, vitamin C and vitamin E (Biewenga et al., 1997; Packer et al., 1995).
The strained 5-membered ring conformation of lipoic acid contributes to its good
scavenging activity (Haenen and Bast, 1991). All the four codrugs in Fig. 1.13 showed
good stability in the gastrointestinal tract and cleaved enzymatically in rat and human
plasma to release the parent drugs. The prolonged release of L-Dopa showed the
effectiveness of the L-DOPA codrugs. Codrugs 1 and 2 were used to test antioxidant
efficacy using superoxide dismutase (SOD) and glutathione peroxidase (GPx) markers.
These enzymes have a central role in the control of reactive oxygen species (ROS). SOD
dismutates highly reactive superoxide into oxygen and hydrogen peroxide. GPx reduces
hydrogen peroxide to water by oxidising GSH. The oxidised form of GSH (GSSG) is
reduced back to GSH by glutathione reductase, as shown in the equations below:

H2O2 + 2 GSH ---> GSSG + 2 H2O
GSSG + NADPH + H+ ----> 2 GSH + NADP+

Codrugs 1 and 2 showed increased GPx activity as compared to L-DOPA alone,
which could indicate a decreased production of free radicals. Also, these codrugs induced
decreased activity of SOD as compared to L-DOPA alone, indicating a reduced
production of superoxide anions.
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Similar results were obtained when codrugs of L-Dopa and glutathione were
constructed with amide linkages (Stefano et al., 2007). Glutathione helps in the
decomposition of toxic peroxide molecules, protects enzymes by maintaining their SH
groups in a reduced state, and is also involved in the repair of oxidized iron-sulfur centers
of the mitochondrial complex. No hydrolysis of these codrugs was observed in
gastrointestinal fluids and L-DOPA was released in plasma via enzymatic hydrolysis. The
codrugs also showed an antioxidant effect using SOD and GPx markers (Fig. 1.14).
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Fig. 1.14 (a) L-Dopa and Glutathione codrug (b) Dopamine and Glutathione codrug
Like glutathione or α-lipoic acid, the other two antioxidants, caffeic acid and
carnosine, were conjugated with L-Dopa (Fig. 1.15) and assessed by evaluating plasmatic
activities of SOD and GPx in rats (Piera et al., 2008). These codrugs were devoid of
significant antioxidant activity, although the literature is full of reports that caffeic acid
and carnosine act as natural antioxidants with hydroxyl radical-scavenging and lipidperoxidase activities.

To overcome the pro-oxidant effects of L-Dopa, the other antioxidants used were
sulfur containing, such as N-acetyl cysteine (NAC), methionine and bucillamine (Fig.
1.16). N-acetylation of cysteine speeds up cysteine absorption and distribution when
given orally. NAC helps in increasing the intracellular concentration of glutathione via
elevating intracellular cysteine levels. NAC is rapidly absorbed, enters cells, and is
rapidly hydrolyzed to cysteine. Methionine is also an intermediate in the synthesis of
cysteine, and helps PC 12 cells against DA–induced nigral cell loss in Parkinson’s
disease by binding to oxidative metabolites of dopamine (Grinberg et al., 2005; Offen et
al., 1996; Martı´nez et al., 1999). Bucillamine is a synthetic cysteine derivative used for
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the treatment of rheumatoid arthritis (Horwitz, 2003). It contains two thiol groups, which
makes it a more powerful antioxidant as compared to NAC and methionine. It can be
easily transported into cells to restore GSH under conditions of oxidative stress and GSH
depletion (Hammond et al., 2001).
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Fig. 1.15 Structures of (a) 3, 4-diacetyloxy-L-dopa methyl ester-caffeic acid codrug
(b) 3, 4-diacetyloxy-L-dopa methyl ester–carnosine codrug
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Fig. 1.16 Codrugs of L-Dopa linked to cysteine, methionine and bucillamine

Six codrugs were constructed using L-Dopa as one of the parent drugs and
NAC/methionine/bucillamine as the other parent drug (Stefano et al., 2006 [2]). All the
codrugs showed good lipophilicity and water solubility for optimal intestinal absorption.
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The stability study at pH 1.3 and in SGF indicated that the codrugs would be stable
enough to pass un-hydrolyzed through the stomach after oral administration. At pH 7.4,
they were stable enough to be absorbed intact from the intestine. In rat and human
plasma, the codrugs hydrolyzed to release the parent drugs, although the release of LDopa from the codrugs was very slow. Next, the antioxidant efficacy of codrugs was
evaluated using a chemiluminescent assay. The comparison was made using NAC; all the
codrugs showed a better antioxidant effect as compared to NAC. The physicochemical
and pharmacokinetic data showed high levels of L-Dopa in the plasma and brain, even 12
h after administration. Codrugs 3 and 4 were able to induce a sustained release of L-Dopa
and dopamine in rat striatum with respect to equimolar doses of L-Dopa. Codrug 4 was
injected intracerebroventricularly, and it resulted in levels of dopamine in the striatum
that were higher than those in L-Dopa-treated rats. This indicated that the codrug had a
longer half-life in brain than L-Dopa (Stefano et al., 2006 [2]).

Benserazide is a Dopa-decarboxylase inhibitor. An L-Dopa codrug with
benserazide had good lipophilicity as compared to either L-Dopa or benserazide (Fig.
1.17). The codrug was stable in aqueous buffer solutions. In plasma, the catechol esters
and amide bonds were efficiently cleaved, releasing the parent drugs in one step (Stefano
et al., 2006 [2]).
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Fig. 1.17 Codrug of L-Dopa with benserazide
1.5 A Codrug strategy in pain management

1.5.1 Opioids and Cannabinoids
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Opioid and cannabinoid interaction in the prevention of pain is very significant,
especially in the case of chronic pain, where higher doses with greater side effects are
encountered. Combination of these two drug types produced an analgesic effect, even
with inactive doses of either drug alone, which suggests the possibility of utilizing
smaller doses yielding fewer side effects and less addiction potential (Cichewicz, 2004).
In addition, opioids exert their analgesic effect on nociceptive pain while cannabinoids
are effective in modulating neuropathic pain. Thus, an opioid-cannabinoid codrug might
be able to cover a broader range of pain. Several articles have been published on the
interaction of opioids with cannabinoids, which are explained further in this chapter.
Keeping the interactions between these two classes of analgesics in mind, various codrug
combinations of opioids and cannabinoids were synthesized in this dissertation work.
These syntheses are discussed in the next chapter.

1.5.2 Pharmacokinetics and Pharmacodynamics of Opioids

Opioids are compounds having morphine-like pharmacological activity. The term
opiate refers to any natural or synthetic agent derived from, or structurally related to
morphine (Thorn, 2009). The endogenous enkephalin peptides and the endorphins are,
therefore, opioids because they are not structurally related to morphine, but have the
same pharmacological activity.
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Fig. 1.18 Structures of Morphine, Codeine and Endogenous Opioids

Fig. 1.18 shows the structures of morphine, codeine and a selection of
endogenous opioids. Codeine and morphine are the major pain relief drugs in the opiate
family. Both drugs are found naturally in the poppy plant, Papaver somniferum, but for
commercial use, codeine is usually synthesized from morphine, which is more abundant
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in nature (Thorn, 2009). In addition to their analgesic effects, both drugs have antitussive
effects and antidiarrheal activity. Side effects include respiratory depression,
constipation, sedation and addiction. Codeine is a less potent agonist at the mu opioid
receptor (OPRM1) compared to morphine, and is considered a safer alternative in an
outpatient setting.

The principal pathways for the metabolism of codeine occur in the liver, although
some metabolism occurs in the intestine and brain. Approximately 50-70% of codeine is
converted to codeine-6-glucuronide by the UGT2B7 glucuronyl transferase enzyme.
Codeine-6-glucuronide has a similar affinity for the mu opioid receptor as codeine.
Approximately 10-15% of codeine is N-demethylated to norcodeine by CYP3A4 (Thorn,
2009). Norcodeine also has a similar affinity to codeine for the mu opioid receptor.
Between 0-15% of codeine is O-demethylated to morphine, the most active metabolite,
which has 200 fold greater affinity for the mu opioid receptor compared to codeine. This
metabolic reaction is performed by CYP2D6. Approximately 60% of this morphine is
glucuronidated to morphine-3-glucuronide (M3G) while 5-10% is glucuronidated to
morphine-6-glucuronide (M6G). These reactions are principally catalyzed by UGT2B7 in
the liver.

Opioids exert their antinociceptive effects via interaction with opioid receptors
(Pan et al., 2008). There are four major opioid receptors, which have already been cloned:
mu, delta, kappa and nociceptin/orphanin FQ receptors (opioid receptor-like 1[ORL1])
(Pan et al., 2008). There is good evidence for the existence of subtypes of mu-, delta- and
kappa-receptors. These receptors are located in brain and spinal cord tissues and each
receptor plays a role in the mediation of pain. The mu receptor is morphine-selective and
is the principal pain-modulating site in the central nervous system. There are two
subtypes of mu receptor: mu1 and mu2. Subtype mu1 is mainly the analgesic site, while
subtype mu2 is responsible for respiratory depression. Opioid receptors belong to the Gprotein-coupled receptor (GPCR) superfamily, and are heterodimeric receptors with
ligand binding and signaling capabilities. These GPCRs possess seven cell membranespanning domains with extracellular ligand binding sites for specific molecules.
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Interactions with those sites result in modulation of signal transduction pathways
involving second messengers such as cAMP, inositol phosphate, or calcium, which is
ultimately translated into cellular responses. Opioid binding can increase calcium ion
release from intracellular calcium ion stores via activation of the second messenger,
phospholipase C.

Chronic opiate administration leads to tolerance and a desensitization of opioid
receptors. In many, but not all instances, a down-regulation of opioid receptors in vivo
occurs following chronic opioid administration (Rotha et al., 1998).

The expression level of different opioid receptors is influenced by different pain
conditions. Pain can be broadly divided into two categories: nociceptive pain, in which
the free peripheral nerve endings are activated by noxious stimuli such as heat, pressure,
etc. This is manifested as a kind of constant, dull and aching pain. Neuropathic pain
occurs as a result of damage to the peripheral or central nervous system. Examples are
diabetic neuropathy, multiple sclerosis, or spinal cord injury. This pain is often described
as “burning and tingling”. It is characterized by hyperalgesia (increased painful response
to noxious stimulus) and allodynia (pain to a previously non-noxious stimulus) (Pan et
al., 2008).

Pain is inadequately managed with currently available drugs, especially for
patients suffering with chronic pain conditions such as cancer or AIDS. Opioids are
considered to be most effective for treatment of nociceptive pain but show little or no
effect in neuropathic pain. In the case of nerve injury, or in diabetic neuropathy, mu
receptor expression is reduced in the spinal dorsal horn, which reduces the
antinociceptive effect of mu receptor agonists (Rotha et al., 1998). Also, long-term use of
opioids such as morphine or oxycodone results in the development of tolerance to the
analgesic effect, and causes drug abuse and dependence, as well as significant side effects
such as respiratory depression, constipation, and cognitive impairment.
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Anticonvulsant drugs such as GABA-pentin (Neurotin ®) and pregablin (Lyrica ®)
are often used to treat neuropathic pain, but have limited efficacies. An antidepressant,
Duloxetine (Cymbalta®) has been recently approved for the treatment of diabetic
neuropathy, but this drug is also associated with significant side-effects (Patacchioli,
2004).

The limitations of currently available treatments for nociceptive and neuropathic
pain clearly indicate the need for new approaches. One approach to address this problem
is to consider combining analgesic drugs from other classes with opioids. The theory
behind this is to lower the dose to avoid side effects, in addition to covering a broad
spectrum of pain, i.e., to treat both nociceptive and neuropathic pain. The two combined
drugs should produce a synergistic effect rather than just an additive effect. In this regard,
one group of drugs that appears particularly promising for combination with the opioids
is the cannabinoids (Patacchioli, 2004).

1.5.3 Pharmacokinetics and Pharmacodynamics of Cannabinoids

Cannabinoids are useful for the treatment of pain, spasticity, glaucoma and other
disorders. But they have numerous side-effects too, such as increase in heart rate,
lowering of blood pressure, appetite stimulation, dry mouth and dizziness (Patacchioli,
2004). The Cannabis plant contains several cannabinoids, one of which
∆
is
tetrahydrocannabinol

9

(∆ -THC)

which

possesses

most

of

the

9

-

characteristic

pharmacological effects (Patacchioli, 2004). Fig. 1.15 shows the chemical structure of ∆ 9THC. It is yellow resinous oil, sticky at room temperature, which hardens upon
refrigeration; it is without smell and has bitter taste. The molecular weight of
∆

9

-THC is

314.45, and the molecular formula is C21H30O2. ∆9-THC is highly insoluble in water but
soluble in ethanol/methanol.
Oral administration of∆ 9-THC leads to erratic uptake of the drug as a result of
degradation by stomach acids and extensive liver first-pass metabolism (Howelett and
Barth, 2002). The measured bioavailability of∆ 9-THC after oral administration (Marinol)
is only 10-20%. Since it is highly lipophilic, high concentrations of the drug are found in
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highly vascularized tissues shortly after oral administration of the drug, which is reflected
in a high volume of distribution of about 10 L/kg.∆

9

-THC also binds strongly to plasma

proteins, only about 3% of the drug being in the unbound form. The major
biotransformation product of∆ 9-THC is the monohydroxy metabolite, 11-hydroxy-∆9THC (THC-OH), which also binds to plasma proteins very strongly (Howelett and Barth,
2002).
More than 100 metabolites of∆
high lipid solubility,∆

9

9

-THC have already been identified. Due to its

-THC is a good substrate for cytochrome P450 mixed-function

oxidases (Rotha et al., 1998; Patacchioli, 2004; Howelett and Barth, 2002). ∆ 9-THC is
hydroxylated at both C11 and C8, and at all the positions of the alkyl side-chain. Fig.
1.19 shows the possible oxidation sites for ∆ 9-THC.

Fig. 1.19 Possible metabolic oxidation sites of ∆9-THC
∆9-THC, like any other very lipophilic drug, has long terminal half-life, due to its
deposition in tissues. The complete elimination time is very difficult to estimate, due to
the slow equilibration of plasma and tissue concentrations. The literature half-life value
varies between 1-4 days, while complete elimination may well take up to 5 weeks (Rotha
et al., 1998; Patacchioli, 2004; Howelett and Barth, 2002).∆ 9-THC is excreted both in
urine and feces as metabolites. Most urinary metabolites are acids. The main metabolite
found in urine is the THC-COOH glucuronide, which, when normalized to the creatinine
concentration, can be used for the detection and monitoring of Cannabis drug abuse. ∆ 9THC also undergoes extensive enterohepatic recycling, which also contributes to its slow
elimination (Rotha et al., 1998; Patacchioli, 2004; Howelett and Barth, 2002).
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Cannabinoid receptors have been identified in both the brain and the immune
system. They are denoted by the abbreviation CB, and numbered in the order of their
discovery by a subscript (Howelett and Barth, 2002). Two distinct cannabinoid receptors,
CB1 and CB2 have been cloned. The CB1 receptor is a GPCR receptor located in the
central nervous system. It is expressed strongly in the basal ganglia, cerebellum,
hippocampus and in the dorsal primary afferent spinal cord region (Howelett and Barth,
2002; Williams et al., 2006). The localization of CB1 receptors clearly indicates their
effectiveness in memory impairment, analgesia and addiction. The CB2 receptor exhibits
48% homology with the CB1 receptor. CB2 receptor mRNA is found mainly in immune
tissues, and is notably absent from normal nervous tissue (Howelett and Barth, 2002).∆ 9THC and other cannabinoid receptor agonists show therapeutic effects as analgesics,
lessen feelings of nausea and vomiting in cancer chemotherapy, cause appetite
stimulation in wasting syndromes, and provide relief from muscle spasms. The main sideeffects are alterations in cognition and memory, dysphoria/euphoria, and sedation.
Synthetic agonists that bind to cannabinoid receptors are usually
∆

9

-THC analogs and

aminoalkylindole compounds. Most notable endogenous cannabinoid ligands are
anandamide

(arachidonoylethanolamide),

2-arachidonoylglycerol,

and

2-

arachidonoylglyceryl ether. Anandamide and 2-arachidonoylglycerol function as
neurotransmitters or neuromodulators, and act as retrograde synaptic messengers
(Howelett and Barth, 2002). They are synthesized by neurons on demand, and undergo
depolarization-induced release from neurons and after their release they are rapidly
removed from the extracellular space by a membrane transport system process. This
process still remains to be fully characterized. Once within the cell, anandamide is
hydrolyzed to arachidonic acid and ethanolamine by fatty acid amide hydrolase (FAAH).

When agonists bind to cannabinoid receptors, they activate a number of signal
transduction pathways via the Gi/o family of G proteins. Free Giα proteins regulate adenyl
cyclase, leading to an inhibition of cyclic AMP production. This inhibits phosphorylation
by protein kinase A, leading to modulation of signaling pathways, especially ion channels
(Williams et al., 2006). An interaction between CB1 receptors and phospholipase C was
demonstrated in cultured cerebellar granule neurons, in which cannabinoid agonists
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augmented the Ca2+ signal in response to NMDA receptor stimulation of K+
depolarization (Howelett and Barth, 2002).

A body of evidence suggests the existence of independent but interacting
mechanisms of modulation of antinociception by cannabinoid and opioid systems
(Hohman et al., 1999). It has been shown previously that
∆

9

-THC and morphine show

synergistic effects in the production of antinociception (Williams et al., 2006). There is a
similar distribution of CB1 cannabinoid and mu opioid receptors in the dorsal horn of the
spinal cord and in central nervous system (Bidaut-Russell and Howlett, 1988). Opioids
and cannabinoids also produce similar effects on calcium levels and cyclic AMP
accumulation through G protein receptors (Reche et al., 1996). Importantly, cannabinoids
have been shown to produce analgesia through interaction with kappa opioid receptors in
the spinal cord by releasing endogenous opioids (Hohman et al., 1999).
A synergism between morphine and ∆ 9-THC has also been observed in the spinal
cord of mice. Inactive doses of both morphine∆and

9

-THC showed a greater than

additive effect when given by i.v. administration (Bidaut-Russell and Howlett, 1988;
Reche et al., 1996). A mixture of these two drugs produced an analgesic effect through
mu opioid receptor- as well as CB1 cannabinoid receptor-mediated pathways.

Since, a codrug strategy has been reported useful for improving the
physicochemical and pharmacokinetic properties of the parent drugs; the next chapter
reports the synthesis of opioid and cannabinoid codrugs. Later on, their pharmacological
and pharmacokinetic evaluation has been carried to compare their efficacies with parent
drugs and physical mixtures of the parent drugs.

Copyright © Harpreet Dhooper 2010
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Chapter 2
Synthesis of Codrugs and Parent drugs
2.1 Synthesis of ∆9-Tetrahydrocannabinol (∆9-THC)
∆9-THC synthesis was carried out in two steps. In the first step, (+)-limonene
oxide (mixture of cis and trans isomers) was added to a stirred suspension of sodium
borohydride and diphenyldiselenide in dry ethanol under a nitrogen atmosphere. The
mixture was refluxed for 2 hrs and then after cooling, hydrogen peroxide was added
drop-wise. After work up, the solvent was evaporated under reduced pressure and column
chromatography was carried out using hexanes:diethyl ether gradient to obtain pure
(1S,4R)-p-mentha-2,8-dien-1-ol

(Rickards

and

Watson,

1980).

The

selenoxide

intermediate was characterized by X-ray diffraction (Fig. 2.1) and (1S,4R)-p-mentha-2,8dien-1-ol was characterized by GC-MS (Fig 2.2) and NMR spectroscopy.

Fig. 2.1 Single crystal X-ray structure of the selenoxide intermediate in the synthesis of
∆9-THC
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In the second step, BF3.Et2O was added drop-wise to a stirred suspension of
(1S,4R)-p-mentha-2,8-dien-1-ol, olivetol and anhydrous magnesium sulfate in methylene
chloride at 0 °C under a nitrogen atmosphere. The mixture was stirred for 2 hrs at 0 °C,
and then anhydrous sodium bicarbonate was added.

After workup, column

chromatography over silica was carried out using a hexanes:diethyl ether gradient to
obtain pure ∆9-THC (Scheme 2.1) (Razdan et al., 1974). The final product was
characterized by GC-MS (Fig. 2.2) and NMR spectroscopy.
Scheme 2.1: Synthesis of ∆ 9-THC
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2.2 Synthesis of (-)-Cannabidiol (CBD)

A GC-MS of (+)-limonene oxide (mixture of cis and trans isomers) was recorded
before starting this synthesis, to check the purity of the compound, and also to help in
monitoring the progress of the initial reaction. In Fig. 2.3, a GC of (+)-limonene oxide is
illustrated which shows the peaks attributed to cis and trans limonene oxides having 90
% matches in the Wiley database.

In the first step of the synthesis of (-)-cannabidiol, morpholine was added to a
stirred solution of LiCl and limonene oxide in ethanol and the reaction mixture was
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heated at 70 °C (Scheme 2.2). The progress of the reaction was monitored by GC-MS.
Fig. 2.4, shows the GC-MS of the reaction after 6 hrs, and after 24 hrs. The GC-MS after
24 hrs showed complete disappearance of the trans-(+)-limonene oxide peak. Longer
reaction times allowed the cis-(+)-limonene oxide to react with morpholine. Thus, the
reaction was stopped after 24 hrs. The solvent was evaporated under reduced pressure
after work up; the product, 4-isopropenyl-1-methyl-2-morpholin-4-yl-cyclohexanol, was
obtained as a yellow oil. The GC-MS of this product is shown in Fig. 2.5 (Gu et al.,
2004).

Fig. 2.2 The GC-MS of ∆9-THC
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Fig. 2.3 The GC-MS of (+)-limonene oxide

Scheme 2.2: Synthesis of (1S,4R)-p-mentha-2,8-dien-1-ol
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In the second step of synthesis of (-)-cannabidiol, hydrogen peroxide was added
to the yellow oil resulting from the first step of the synthesis, and the resulting solution
was heated for 4 hrs.10 % Pd on C was then added to decompose the remaining hydrogen
peroxide, and the reaction mixture was filtered through a pad of celite. The filtrate was
evaporated under reduced pressure to afford yellow oil. Silica gel column
chromatography was carried out to purify the compound using a hexanes:ethyl acetate
gradient followed by elution with methanol, to afford a pure fraction of 4-isopropenyl-1methyl-2-(4-oxy-morpholin-4-yl)-cyclohexanol.

4-Isopropenyl-1-methyl-2-(4-oxy-morpholin-4-yl)-cyclohexanol was dissolved in
toluene and silica was added. The resulting mixture was heated to reflux with stirring.
The literature procedure recommends the use of a Dean and Stark apparatus, but product
formation was observed when under these conditions. As an alternative, the solution was
refluxed overnight and the silica was then removed by filtration. The filtrate was
evaporated under reduced pressure to afford a brown oil, which consisted of the product,
(1S,4R)-p-mentha-2,8-dien-1-ol and a small amount of (1R,4R)-p-mentha-2,8-dien-1-ol
as a byproduct. The crude (1S,4R)-p-mentha-2,8-dien-1-ol was purified by silica gel
column chromatography using a hexanes:diethyl ether gradient and the final product was
characterized by GC-MS (89% match with Wiley database) (Fig. 2.6) and NMR
spectroscopy (Chen et al., 2007).

In the last step of the synthesis, a mixture of olivetol, zinc chloride, water and
dichloromethane was refluxed and (1S,4R)-p-mentha-2,8-dien-1-ol was added drop-wise
(Scheme 2.3). It is advisable to add (1S,4R)-p-mentha-2,8-dien-1-ol very slowly to avoid
the formation of side-products. The progress of the reaction was monitored by GC-MS.
After the completion of the reaction, the solvent was evaporated, and the crude mixture
was characterized by GC-MS, which indicated that it contained (-)-cannabidiol,
abnormal-cannabidiol (abn-CBD), olivetol and traces of
∆

9

-THC (Fig. 2.7). Column

chromatography over silica gel was carried out on the crude product using a
hexanes:diethyl ether gradient. The fractions obtained were characterized by GC-MS and
NMR spectroscopy (Choi et al., 2004). A pure fraction of (-)-cannabidiol was obtained
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and was characterized by GC-MS (Fig. 2.8). An NMR spectrum of the synthesized (-)cannabidiol compared favorably with that of (-)-cannabidiol reported by Gutman et al.,
2006.

GC after 6 hrs

GC after 24 hrs

Fig. 2.4 GC-MS of reaction mixture for the synthesis of 4-isopropenyl-1-methyl-2-(4oxy-morpholin-4-yl)-cyclohexanol after 6 hrs and 24 hrs
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Fig. 2.5 The GC-MS of 4-isopropenyl-1-methyl-2-(4-oxy-morpholin-4-yl)-cyclohexanol
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ΟΗ

Fig. 2.6 The GC-MS of (1S,4R)-p-mentha-2,8-dien-1-ol
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Scheme 2.3: Synthesis of (-)-cannabidiol and abnormal-cannabidiol
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Fig. 2.7 The GC-MS of the crude mixture from (-)-cannabidiol synthesis
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OH

Fig. 2.8 The GC of synthesized (-)-cannabidiol
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Fig. 2.9(a) The MS of synthesised (-)-cannabidiol
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OH

HO

Fig. 2.9 (b) The MS of a reference standard of (-)-cannabidiol

Fig. 2.10 The GC of abn-cannabidiol
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Fig. 2.11 (a) MS of abn-cannabidiol and (b) MS of a reference standard of (-)-cannabidiol
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2.3 Codeine-∆9-Tetrahydrocannabinol (Cod-THC) Codrug Synthesis

Before starting the synthetic work with expensive controlled substances such as
codeine and ∆9-THC, coupling reactions were initially carried out with model compounds
or chemical-mimics of the drug molecules to optimize the desired chemistry. 3Ethylphenol was chosen as the model compound for both codeine and ∆9-THC.

1

2

3

RO
H

OH
N

O

HO

H

O

H
HO
Bu n
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R=Me, Codeine

Fig. 2.12 Structures of morphine, codeine (1), 3-ethylphenol (2) and Δ9-THC (3)
Since the essential conjugation chemistry in the synthesis of the Cod-THC codrug
is the formation of a carbonate linkage, reactions were initiated to generate carbonate
linkages with phenols. Initially, a symmetrical carbonate ester of 3-ethylphenol was
formed utilizing triphosgene and pyridine (Scheme 2.4) (Burk and Roof, 1993).

Scheme 2.4: Synthesis of a symmetrical carbonate of 3-ethylphenol
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Unfortunately, 3-ethylphenol obtained from Aldrich was only 80% pure, the
major of the impurity being 4-ethylphenol, thus a pure sample of desired product was
unattainable. Due to this problem, use of 3-ethylphenol in the model reactions was
replaced with 4-ethylphenol, since 4-ethylphenol from Aldrich was 98% pure. The same
conjugation reaction was carried out with 4-ethylphenol and afforded the desired
symmetrical carbonate.

The next aim was to form a carbonate linked product using two different phenols.
For this purpose 4-ethylphenol and 5,6,7,8-tetrahydro-2-naphthol were used as model
compounds. The reaction between these two phenols in the presence of triphosgene and
triethyl amine produced 3 different carbonates, two symmetrical carbonates along with
the desired unsymmetrical carbonate. GC-MS analysis showed almost equal quantities of
all three carbonates in reaction mixture (Scheme 2.5).

Scheme 2.5: Conjugation of two different phenolic compounds utilizing triphosgene

O
O
Et 3N

O
+ Cl 3C

O

O

DCM
-78 oC

CCl 3 + HO

OH

+

O

O
O

O
+
O

O
O
Desired Product

In the above reaction, as there was no selectivity observed for the formation of the
desired unsymmetrical carbonate over the two symmetrical carbonates, it was anticipated
that purification of the unsymmetrical carbonate would present a difficult challenge.
Thus, a different synthetic approach was devised utilizing the intermediacy of a
chloroformate analogue. Initially, one of the phenolic starting materials was converted to
a chloroformate derivative, and then the other phenolic starting material was reacted with
the chloroformate derivative to afford the unsymmetrical carbonate product (Scheme 2.6)
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(Martin et al., 2006). Utilizing triethylamine as a base in the second step of the coupling
reaction afforded better yield and less amount of side product formation (Scheme 2.7).

Scheme 2.6: Synthesis of an unsymmetrical carbonate of 4-ethylphenol and 5,6,7,8tetrahydro-2-naphthol
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Scheme 2.7: Synthesis of an unsymmetrical carbonate of 4-ethylphenol and 5,6,7,8tetrahydro-2-naphthol utilizing triethylamine
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Since codeine contains an OH group and a basic tertiary N-atom, 3-quinuclidinol
was chosen as a more appropriate chemical-mimic for codeine. 4-Ethylphenol was
retained as the model molecule∆for

9

-THC. In the next series of reactions the
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chloroformate of 4-ethylphenol was initially formed and then reacted with 3quinuclidinol to form the carbonate of 4-ethylphenol and 3-quinuclidinol (Scheme 2.8).

Scheme 2.8: Synthesis of an unsymmetrical carbonate of 4-ethylphenol and 3quinuclidinol
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There were some problems associated with the formation of the chloroformate
intermediate. The reaction was never clean, and there was always formation of a
symmetrical carbonate as a side-product together with the formation of the desired
chloroformate. Due to this problem a new synthetic method was sought for the exclusive
synthesis of the unsymmetrical carbonate.

p-nitrophenylchloroformate analogues have been described in the literature for the
formation of unsymmetrical carbonates and carbamates (Anderson and McGregor, 1957).
Initially, an alcohol (A) is reacted with p-nitrophenylchloroformate to form the carbonate
conjugate of A and p-nitrophenol. This intermediate is then reacted with another
alcohol/phenol (B) to form the carbonate conjugate of A and B. In the second step, the
good leaving group property of p-nitrophenol is advantageous in selective formation of
the desired unsymmetrical carbonate (Scheme 2.9).

3-Quinuclidinol was allowed to react with p-nitrophenylchloroformate in the
presence of a base to form the carbonate of 3-quinuclidinol and p-nitrophenol (Scheme
2.9a).
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Scheme 2.9a: Synthesis of carbonate of 3-quinuclidinol and p-nitrophenol
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In the next step, the carbonate of 3-quinuclidinol and p-nitrophenol was allowed
to react with codeine to form the desired unsymmetrical 3-quinuclidinol-codeine
carbonate (Scheme 2.9b).

Scheme 2.9b: Synthesis of unsymmetrical 3-quinuclidinol-codeine carbonate
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The carbonate ester of 3-quinuclidinol and codeine was also successfully
synthesized via the alternative route by first forming the p-nitrophenol carbonate of
codeine and then reacting this intermediate with 3-quinuclidinol (Scheme 2.10).
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Scheme 2.10: Synthesis of unsymmetrical carbonate codeine and 3-quinuclidinol via the
intermediacy of codeine-p-nitrophenol carbonate
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The latter approach was problematic, in that formation of the symmetrical
carbonate of codeine was formed along with the desired unsymmetrical carbonate.

Scheme 2.11: Formation of carbonate of codeine and p-nitrophenol using triethylamine
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O

O

H
O

This problem was solved by utilizing a different base (DMAP), and by varying
the reaction time and temperature (Scheme 2.12). The purity of the unsymmetrical
carbonate was checked by NMR spectroscopy and by analytical HPLC. Fig. 2.14 shows
the chromatograms of p-nitrophenol, codeine,∆

9

-THC and codeine-p-nitrophenol

carbonate (Cod-PNP). A UV wavelength of 220 nm was used for the detection. An
Apollo C18 reverse phase column was used as the stationary phase, and 80:20
Acetonitrile:NH4OAc buffer (pH 4.5) was used as the mobile phase with a 1 ml/min flow
rate.

Scheme 2.12: Formation of carbonate of codeine and p-nitrophenol using DMAP
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The next step was to form the actual codrug by reacting the p-nitrophenol
carbonate of codeine with∆

9

-THC. This reaction was carried out in the presence of

DMAP as a base, and the reaction mixture was refluxed overnight. Formation of the
product was confirmed by recording the MALDI spectrum of the product from the
reaction mixture (Scheme 2.13).
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Fig. 2.13 MALDI spectrum of codeine-p-nitrophenol carbonate
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Fig. 2.14 HPLC chromatograms of different analytes (p-nitrophenol, codeine, ∆ 9-THC,
codeine-p-nitrophenol carbonate)
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Scheme 2.13: Synthesis of carbonate of codeine and ∆ 9-THC
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The above reaction was carried out several times by varying the base (DMAP or
triethylamine) and varying the reaction temperatures and solvents, but the reaction never
went to completion. Although the MADLI spectrum showed evidence for the formation
of the desired codrug, TLC monitoring of the reaction mixture showed only a faint spot
of the product and intense spots of the starting materials. Since conventional chemical
reactions could not solve the problem of incomplete conversion to product, microwave
reactions were explored (de la Hoz et al., 2005). In an initial attempt, the carbonate of
codeine and p-nitrophenol was reacted with 4-ethylphenol in a microwave oven in
presence of a base (TEA) and in absence of any solvent (Scheme 2.14a). The reaction
mixture was irradiated for 30 seconds followed by TLC monitoring. No further progress
of the reaction was noticed after 2 minutes of total microwave irradiation time.

Scheme 2.14 (a): Synthesis of unsymmetrical carbonate of codeine and 4-ethylphenol
utilizing microwave irradiation

MeO
MeO

NO2
N

O

TEA

H

O

O
O

OH

Microwave
2 mins

55

N

O

+
O
O

H
O

In another attempt, the reaction between the carbonate of codeine and pnitrophenol and 5,6,7,8-tetrahydro-2-naphthol was performed under microwave
conditions. The reaction mixture was irradiated for 30 seconds followed by TLC
monitoring. No further progress of the reaction was noticed after 2 mins of total
microwave irradiation time (Scheme 2.14b).

Scheme 2.14(b): Synthesis of unsymmetrical carbonate of codeine and 5,6,7,8tetrahydro-2-naphthol utilizing microwave irradiation
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Both of the model microwave reactions showed positive results and showed the
evidence of formation of the desired carbonates (around 20% conversion to product) in
both the MALDI and NMR spectra.

Next, the microwave-mediated reaction between the carbonate of codeine and pnitrophenol and∆

9

-THC was performed. The reaction mixture was heated in the

microwave oven for 30 seconds in the presence of TEA and then analyzed by HPLC. The
results indicated that the desired product had been formed but the reaction was still
incomplete, and in addition to the starting materials, the symmetrical carbonate was also
present in the reaction mixture (Scheme 2.14c).
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Scheme 2.14(c): Synthesis of unsymmetrical carbonate of codeine and∆ 9-THC utilizing
microwave irradiation
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Since microwave-mediated reactions were not a complete success, a conventional
approach was again explored, focusing first on the reaction of the para-nitrophenol
carbonate of codeine with ∆ 9-THC. In this reaction, ∆ 9-THC was treated first with NaH at
low temperature, followed by drop-wise addition of the p-nitrophenol carbonate of
codeine (Scheme 2.15). The product yield obtained was better than the previous attempts
(43%). MALDI analysis and NMR spectral analysis showed no sign of formation of the
symmetrical carbonate of codeine.

Silica gel column

chromatography of the

reaction product

using

a

dichloromethane-methanol gradient was performed to purify the compound. MALDI,
HRMS and NMR spectral analysis confirmed structure of the pure Cod-THC codrug
(Fig. 2.15, 2.16).

The analysis of the Cod-THC codrug by HPLC-UV assay was carried out.
Detection was at 220 nm and an Apollo ® C18 (5 µm, 3.9 x 150 mm) column, equipped
with a guard column (Nova-Pak® C18; 3.9 x 20 mm; 4µ) was used as the stationary
phase; methanol/6mM phosphate buffer containing 0.025% heptafluorobutyric acid
(HFBA), pH adjusted to 6.9 with triethylamine, was used as the mobile phase. A gradient
program with a flow rate of 1mL/min was used for the elution of the Cod-THC codrug
molecule. Fig. 2.17 shows the chromatogram of the Cod-THC codrug.
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Scheme 2.15: Synthesis of unsymmetrical carbonate of codeine and
∆

9

-THC utilizing a

stronger base (NaH)
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Fig. 2.15 The MALDI analysis of the Cod-THC codrug
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Fig. 2.16 High resolution electron impact ionization mass spectrum of the Cod-THC
codrug
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Fig. 2.17 HPLC chromatogram of chromatogram the Cod-THC codrug
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2.4 Synthesis of the Codeine-(-)-Cannabidiol codrug (Cod-CBD)

The Cod-CBD codrug was synthesized in a similar manner to the successful
synthesis of the Cod-THC codrug. First, the intermediate para-nitrophenol carbonate of
codeine was prepared. Then, (-)-cannabidiol was treated with NaH and then the paranitrophenol carbonate of codeine was added drop-wise to the reaction mixture. Scheme
2.16 shows the synthesis of the Cod-CBD codrug. Silica gel column chromatography was
again carried out in order to purify the desired codrug using a dichloromethane-methanol
gradient. The compound was characterized by NMR spectroscopy, HRMS (Fig. 2.18) and
LC-MS analysis (Fig. 2.19).

Scheme 2.16: Synthesis of carbonate of codeine and (-)-cannabidiol
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2.5 Synthesis of the Codeine-abn-Cannabidiol codrug (Cod-abnCBD)

The Cod-abnCBD codrug was synthesized in a similar manner to the Cod-THC
and Cod-CBD codrugs. Scheme 2.17 depicts the synthesis of the Cod-abnCBD codrug.
Silica gel column chromatography was performed again to obtain a pure sample of the
desired codrug using a dichloromethane-methanol gradient. The compound was
characterized by NMR and mass spectral analysis (Fig. 2.20).

Scheme 2.17: Synthesis of carbonate of codeine and abnormal-cannabidiol
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Fig. 2.18 High-resolution electron impact ionization mass spectrum of the Cod-CBD
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Fig. 2.19 LC-MS analysis of the Cod-CBD codrug
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Fig. 2.20 High resolution electron impact ionization mass spectrum of the Cod-abnCBD
codrug
2.6 Synthesis of the 3-O-Acetylmorphine-∆9-tetrahydrocannabinol codrug (AcMorTHC)

AcMor-THC codrug synthesis was carried out in three steps. In the first step, 3-Oacetylmorphine was synthesized by regioselective 3-O-acetylation of morphine free base
using acetic anhydride and sodium bicarbonate. 3-O-Acetylmorphine was then allowed to
react with para-nitrophenylchloroformate to afford the 6-O-carbonate of 3-Oacetylmorphine and para-nitrophenol. Finally, the intermediate carbonate was allowed to
react with phenoxide ion of∆ 9-THC to afford the desired product, 3-O-acetylmorphine∆9-tetrahydrocannabinol

carbonate

(AcMor-THC).

3-O-Acetylmorphine,

3-O-

acetylmorphine-para-nitrophenol carbonate intermediates and the final AcMor-THC
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codrug product were all characterized by GC-MS, LC-MS, ESI-MS, and NMR and
HRMS analysis (Scheme 2.18) (Crooks et al., 2002).

Fig. 2.21 GC-MS spectrum of 3-O-acetylmorphine
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Scheme 2.18a: Synthesis of 3-O-acetylmorphine
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Scheme 2.18 b:Synthesis of 6-O-carbonate of 3-O-acetylmorphine and para-nitrophenol
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Scheme 2.18c: Synthesis of 3-O-acetylmorphine-∆9-tetrahydrocannabinol carbonate
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Fig. 2.22 ESI-MS of 3-O-acetylmorphine-para-nitrophenol carbonate (AcMor-PNP)

Fig. 2.23 High resolution electron impact ionization mass spectrum of the 3-Oacetylmorphine-∆9-tetrahydrocannabinol codrug
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Fig. 2.24 ESI-MS of 3-O-acetylmorphine-∆9-tetrahydrocannabinol codrug

Experimental section

General Procedures. All experimental procedures were carried out under
nitrogen and in oven-dried glassware unless otherwise mentioned. Solvents and reagents
were obtained from commercial vendors. All solvents were removed by evaporation
using a rotary evaporator unless indicated otherwise.
1

H and

13

C NMR spectra were recorded on Varian 300MHz and 500MHz

spectrometers. HPLC analyses were carried on an Agilent 1100 series Quatpump,
equipped with a photodiode array detector and a computer integrating apparatus. GC-MS
analyses were carried out on an Agilent 6890 GC instrument attached to a 593 massselective detector. Microwave reactions were carried out on a Biotage 355422-AD
microwave synthesizer. High-resolution mass spectrometry was performed by the
University of Kentucky Mass Spectrometry facility. X-ray crystallography was
performed by the University of Kentucky Crystallographic facility.
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Synthesis of ∆9-Tetrahydrocannabinol.

OH

(1S,4R)-p-Mentha-2,8-dien-1-ol. Sodium borohydride (0.266 g, 7.02 mmol) was
added portion-wise to a stirred suspension of diphenyldiselenide (1.0 g, 3.2 mmol) in dry
ethanol (16 mL) under nitrogen atmosphere. A mixture of cis- and trans- limonene oxide
(0.870 g, 5.72 mmol) was added, and the resultant mixture was refluxed for 2 h. After
cooling in an ice-bath, THF (15 mL) was added followed by drop-wise addition of 35%
v/v hydrogen peroxide (1.7 mL). The solution was allowed to warm to ambient
temperature and stirred for 5 h, and then diluted with water (40 mL). The organic layer
was separated. The aqueous layer was extracted with methylene chloride, and the
combined organic liquors were washed with 10% aqueous sodium carbonate, water, and
saturated brine, dried over anhydrous sodium sulfate and concentrated on a rotary
evaporator. The residue containing the selenoxide intermediate was utilized in the next
step without any further purification. The selenoxide intermediate was heated for 8 h in
refluxing chloroform (13.5 mL) under a nitrogen atmosphere. After cooling, the solvent
was evaporated and the residue was extracted with diethyl ether. The solvent was
evaporated and the crude product was purified through silica gel column chromatography
to afford pure (1S,4R)-p-mentha-2,8-dien-1-ol (0.213 g, 25%). The elution was carried
out with hexanes and increasing portions of diethyl ether up to 5:1 of hexanes:diethyl
ether. 1H NMR (300 MHz, CDCl3): δ 5.63 (2H, m), 4.70 (2H, m), 2.59 (1H, m), 1.411.90 (7H, m), 1.25 (3H, s) ppm;

13

C NMR (300 MHz, CDCl3): δ 148.1, 133.9, 132.1,

110.6, 67.4, 43.4, 36.7, 29.4, 24.9, 20.8 ppm; GC-MS M+ 152 m/z.

OH

O

68

∆9-Tetrahydrocannabinol. Boron trifluoride etherate (0.09 mL) was added dropwise to an ice-cold stirred suspension of (1S,4R)-p-mentha-2,8-dien-1-ol (0.213 g, 1.4
mmol), olivetol (0.263 g, 1.38 mmol) and anhydrous magnesium sulfate (0.185 g) in
methylene chloride (9.25 mL) under nitrogen. The mixture was stirred for 2 h at 0 °C,
and then anhydrous sodium bicarbonate (0.462 g) was added. Stirring was continued until
the color faded to a light brown, and the reaction mixture was then filtered and
evaporated to provide a brown gum. The crude product of ∆9-THC was purified using
silica gel column chromatography. Elution was carried out with hexanes with increasing
portion of diethyl ether in hexanes (up to 30:1 hexanes:diethyl ether) to afford a pure
fraction of ∆9-THC (100 mg, 22%). 1H NMR (300 MHz, CDCl3): δ 6.29 (1H, br s), 6.25
(1H, d, J=1.2 Hz), 6.12 (1H, d, J=1.2 Hz), 4.78 (1H, s), 3.18 (1H, br d), 3.42 (2H, t, J=7.2
Hz), 1.20-2.21 (17H, m), 1.07 (3H, s), 0.86 (3H, t, J=7.2 Hz) ppm; 13C NMR (300 MHz,
CDCl3): δ 154.8, 154.2, 142.9, 134.5, 123.8, 110.2, 109.2, 107.7, 77.4, 46.0, 35.8, 33.8,
31.8, 31.4, 31.0, 27.9, 25.3, 23.7, 22.9, 19.6, 14.4 ppm; GC-MS M+ 314 m/z.
Synthesis of (-)-Cannabidiol and abn-Cannabidiol.

O

OH
N

4-Isopropenyl-1-methyl-2-morpholin-4-yl-cyclohexanol. (+)-Limonene oxide
(a mixture of cis and trans isomers) (5.0 g, 0.033 moles) was dissolved in ethanol (16
mL) and LiCl (2.247 g, 0.053 moles) was added while stirring the solution. Morpholine
(4.295 g, 0.049 moles) was added drop-wise and the reaction mixture was heated at 70 °C
for 24 hours. The progress of the reaction was monitored by GC-MS. After almost all of
the trans-(+)-limonene oxide had been consumed solvent was evaporated under reduced
pressure and the residue was taken up into methylene chloride solvent (100 mL). The
organic solution was washed with water (80 mL) and then extracted into 2M hydrochloric
acid (2 x 60 mL) and the aqueous acidic solution was washed with methylene chloride (2
x 50 mL). The aqueous solution was basified to pH 10 by addition of 2M sodium
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hydroxide. The basic aqueous solution was extracted with diethyl ether (4 x 60 mL) and
the organic liquors washed with water (3 x 50 mL). The diethyl ether solution was dried
over anhydrous sodium sulfate and the solvent was evaporated under reduced pressure.
The desired product was obtained as yellow oil (3.38g, 43%). 1H NMR (300 MHz,
CDCl3): δ 4.94 (2H, m), 4.85 (1H, m), 3.70 (4H, m), 2.72 (2H, m), 2.52 (4H, m), 2.10
(1H, m), 2.05 (1H, m), 1.98 (1H, m), 1.74 (3H, s), 1.60 (4H, m), 1.21 (3H, s) ppm; 13C
NMR (300 MHz, CDCl3): δ 145.6, 111.3, 73.0, 67.9, 67.8, 52.3, 45.8, 39.3, 36.0, 25.3,
24.9, 22.8, 22.7 ppm; GC-MS M+ 239 m/z.

O

OH
N
O

4-Isopropenyl-1-methyl-2-(4-oxy-morpholin-4-yl)-cyclohexanol.

4-

Isopropenyl-1-methyl-2-morpholin-4-yl-cyclohexanol (3.596 g, 0.015 moles) was
dissolved in ethanol (21 mL) and 35 % v/v hydrogen peroxide (7.52 mL) was added
drop-wise. The solution was heated at 50 °C for 4 h. 10 % Pd on C (20.32 mg) was added
at room temperature, the mixture was stirred for 2 h, and the solvent was evaporated
under reduced pressure to afford a yellow oil. This oil was submitted to silica gel column
chromatography using a hexanes:ethyl acetate gradient with the final elution with
methanol to afford the desired product (3.38 g, 88%). 1H NMR (300 MHz, CDCl3): δ
4.99 (1H, m), 4.80 (1H, m), 4.48 (2H, m), 3.69 (3H, m), 3.38 (2H, m), 3.20 (1H, m), 2.81
(1H, m), 2.60 (1H, m), 2.20 (1H, m), 1.46-2.00 (12H, m) ppm;

13

C NMR (300 MHz,

CDCl3): δ 143.9, 112.1, 80.1, 73.7, 65.3, 61.5, 61.3, 59.4, 39.8, 39.3, 28.7, 24.7, 23.6,
22.6 ppm.

OH
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(1S,4R)-p-Mentha-2,8-dien-1-ol. 4-Isopropenyl-1-methyl-2-(4-oxy-morpholin-4yl)-cyclohexanol (5.41 g, 0.021 moles) was dissolved in toluene (94 mL) and silica (1.3
g) was added. The reaction mixture was heated to reflux with stirring overnight. The
silica was then removed by filtration. The filtrate was evaporated under reduced pressure
to afford a brown oil. This oil was dissolved in methylene chloride (50 mL) and washed
with 2M hydrochloric acid (2 x 30 mL). The methylene chloride solution was washed
with water (2 x 25 mL) and finally dried over anhydrous sodium sulfate. The solvent was
evaporated under reduced pressure to afford the crude product (1S,4R)-p-mentha-2,8dien-1-ol. The crude product was chromatographed on silica using a hexanes-diethyl
ether gradient to afford pure (1S,4R)-p-mentha-2,8-dien-1-ol (0.77 g, 24%). 1H NMR
(300 MHz, CDCl3): δ 5.63 (2H, m), 4.70 (2H, m), 2.59 (1H, m), 1.41-1.90 (7H, m), 1.25
(3H, s) ppm; 13C NMR (300 MHz, CDCl3): δ 148.1, 133.9, 132.1, 110.6, 67.4, 43.4, 36.7,
29.4, 24.9, 20.8 ppm; GC-MS M+ 152 m/z.

OH

HO

HO
abn-CBD

CBD

OH

(-)-Cannabidiol and abn-Cannabidiol. A mixture of olivetol (1.18 g, 6.55
mmol), zinc chloride (1.35 g, 0.0429 mmol) water (0.115 mL, 0.029 mmoles) and
methylene chloride (11.4 mL) was refluxed for 1 h. (1S,4R)-p-Mentha-2,8-dien-1-ol (1.0
g, 6.57 mmol), dissolved in methylene chloride was then added drop-wise and the
mixture refluxed for an additional 1 h. the progress of the reaction was monitored by GCMS. After complete consumption of (1S,4R)-p-mentha-2,8-dien-1-ol, the solution was
cooled to ambient temperature, ice cold water (5 mL) was then added and the mixture
stirred for 20 min. The organic phase was washed with water (10 mL), 5% sodium
bicarbonate (10 mL), and brine (10 mL), dried and concentrated under reduced pressure.
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The crude mixture was fractioned on silica gel column using a hexanes/diethyl ether
gradient to afford both (-)-cannabidiol (0.64 g, 31%) and abn-cannabidiol (0.39 g, 19%).
Cannabidiol: 1H NMR (300 MHz, CDCl3): δ 6.27 (1H, br s), 6.25 (1H, br s), 6.20 (1H, br
s), 5.99 (1H, s), 5.58 (1H, s), 4.66 (2H, m), 4.56 (1H, m), 3.85 (1H, dm), 2.45 (2H, t),
2.21 (1H, m), 2.12 (1H, m), 1.86 (2H, m), 1.80 (3H, s), 1.60 (3H, s), 1.55 (2H, q), 1.31
(4H, m), 0.88 (3H, t) ppm;

13

C NMR (300 MHz, CDCl3): δ 149.5, 143.1, 140.2, 124.2,

113.9, 110.9, 109.8, 108.1, 46.4, 37.5, 35.8, 31.8, 30.9, 30.7, 28.7, 23.9, 22.8, 20.9, 14.4
ppm; GC-MS M+ 314 m/z.
abn-Cannabidiol: 1H NMR (300 MHz, CDCl3): δ 6.22 (1H, d), 6.20 (1H, d), 6.06 (1H, s),
5.53 (1H, br s), 4.78 (1H, s), 4.65 (1H, t), 4.47 (1H, br s), 3.53 (1H, dm), 2.58 (1H, m),
2.48 (1H, m), 1.67-2.31 (8H, m), 1.54 (3H, s), 1.47 (2H, m), 1.32 (4H, m), 0.90 (3H, t)
ppm;

13

C NMR (300 MHz, CDCl3) δ 156.5, 154.6, 147.7, 144.1, 139.9, 124.8, 120.1,

111.6, 108.7, 102.3, 45.2, 40.3, 34.3, 32.2, 31.4, 30.5, 28.4, 23.9, 22.9, 21.6, 14.4 ppm;
GC-MS M+ 314 m/z.
Synthesis of Codeine-∆9-Tetrahydrocannabinol Codrug.

MeO
NO2
N

O
H

O

O
O

Codeine-p-nitrophenol Carbonate. All glasswares were oven-dried and cooled
under a nitrogen atmosphere. Codeine (0.05 g, 0.16 mmol) was placed in a round bottom
flask under a nitrogen atmosphere and was dissolved in 2 mL of dry chloroform. The
solution was cooled to 0 °C. DMAP (0.023 g, 0.192 mmol) was then added to the
solution and the mixture stirred for 5 min. para-Nitrophenylchloroformate (0.037 g, 0.18
mmol) was dissolved in 3 mL of dry chloroform and the solution was added to the
reaction mixture drop-wise, the mixture was allowed to warm to the ambient temperature.
The progress of the reaction was monitored by TLC. After completion of the reaction, the
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mixture was diluted with chloroform (15 mL). The chloroform layer was washed 5 times
with 10 mL 50% NaHCO3 solution and with brine (10 mL), dried over anhydrous sodium
sulfate and concentrated to afford a solid product (0.032 g, 41 %). 1H NMR (300 MHz,
CDCl3): δ 8.27 (2H, dd), 7.45 (2H, dd), 6.66 (1H, d), 6.56 (1H, d), 5.70 (1H, dd), 5.52
(1H, dd), 5.16 (2H, m), 3.82 (3H, s), 3.36 (1H, m), 3.04 (1H, d), 2.75 (1H, m), 2.58 (1H,
dd), 2.43 (3H, s), 2.36 (1H, dt), 2.29 (1H, dd), 2.03 (1H, dt), 1.88 (1H, d) ppm; 13C NMR
(300 MHz, CDCl3): δ 156.1, 152.2, 146.7, 145.3, 142.7, 130.4, 127.4, 126.7, 126.6,
125.6, 122.2, 121.9, 119.9, 115.0, 114.5, 87.4, 72.4, 59.5, 56.9, 46.9, 43.1, 42.6, 40.5,
35.3, 20.6 ppm; MS (ESI): (M+1) 465 m/z.

MeO
Bu n

N

O
O
H
O

H

O

O

H

Codeine-∆9-Tetrahydrocannabinol Carbonate. All glasswares were oven dried
and cooled under a nitrogen atmosphere.∆ 9-THC (0.053 g, 0.17 mmol) was placed in a
round bottom flask under a nitrogen atmosphere and was dissolved in 2 mL of dry THF.
The solution was cooled down to 0 °C. NaH (0.09 g, 0.22 mmol) was added to the
solution and allowed to stir for 5 min. Codeine-p-nitrophenol carbonate (0.078 g, 0.17
mmol), dissolved in 3 mL of dry THF was added to the reaction mixture drop-wise and
the mixture was allowed to warm to the ambient temperature. The progress of the
reaction was monitored by TLC. After the completion of the reaction, the mixture was
filtered through a pad of celite and then the organic filtrate was concentrated under
reduced pressure to afford yellow oil. The organic residue was dissolved in chloroform
(20 mL), the organic layer was washed with 50% sodium bicarbonate solution (3 x 10
mL), water (10 mL), and brine (10 mL), dried over sodium sulfate and concentrated
under reduced pressure to afford a brownish solid. The crude product was purified using
silica gel column chromatography and a methylene chloride-methanol mixture as eluent,
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to afford the pure product (0.046 g, 43%). 1H NMR (300 MHz, CDCl3): δ 6.71-6.55 (4H,
m), 6.06 (1H, br s), 5.76 (1H, d), 5.48 (1H, dt), 5.15 (2H, m), 3.93 (3H, s), 3.38 (1H, m),
3.19 (1H, m), 3.06 (1H, d), 2.74 (1H, m), 2.60-1.29 (27H, m), 1.11 (3H, s), 0.89 (3H, t)
ppm;

13

C NMR (300 MHz, CDCl3): δ 154.5, 152.8, 149.9, 146.9, 143.0, 142.4, 134.9,

130.6, 129.9, 127.9, 126.9, 126.5, 123.1, 119.5, 115.9, 115.7, 115.0, 114.7, 113.9, 87.9,
72.2, 59.3, 57.3, 46.9, 45.7, 43.3, 42.9, 40.9, 35.7, 34.4, 31.8, 31.4, 30.8, 27.7, 25.2, 23.6,
22.8, 20.7, 19.7, 14.4 ppm; MS (ESI): (M+1) 640 m/z; HRMS: calcd. for C40H49NO6
(M+) m/z 639.3559, found m/z 639.3556.

MeO
N

O
O
O

H
O

OH

Codeine-(-)-Cannabidiol Carbonate Codrug. (-)Cannabidiol (0.175 g, 0.557
mmol) was placed in a round bottom flask under a nitrogen atmosphere and was
dissolved in 4 mL of dry THF. The solution was cooled n to 0 °C. NaH (0.028 g, 0.72
mmol) was added to the solution and allowed to stir for 5 min. Codeine-p-nitrophenol
carbonate (0.258 g, 0.56 mmol), dissolved in 4 mL of dry THF was added to the reaction
mixture drop wise and the reaction mixture was allowed to warm to the ambient
temperature. The progress of the reaction was monitored by TLC. After the completion of
the reaction, the mixture was filtered through a pad of celite and concentrated under
reduced pressure. Obtained residue was dissolved in methylene chloride (25 mL), washed
with 50% sodium bicarbonate solution (3 x 15 mL), water (15 mL), and brine (10 mL),
dried and concentrated under reduced pressure to afford a crude solid. The crude mixture
was submitted to silica gel column chromatography using a methylene chloride/methanol
gradient to afford the pure product (0.164 g, 47%). 1H NMR (300 MHz, CDCl3): δ 6.67
(1H, d), 6.62 (1H, d), 6.57-6.51 (2H, m), 5.73 (1H, d), 5.56 (1H, s), 5.48 (1H, dt), 5.00
(1H, dd), 5.09 (1H, m), 4.57 (1H, t), 4.45 (1H, br s), 3.85 (3H, s), 3.78 (1H, dm), 3.39
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(1H, m), 3.06 (1H, d), 2.76 (1H, m), 1.49-2.64 (23H, m), 1.31 (4H, m), 0.89 (3H, t) ppm;
13

C NMR (300 MHz, CDCl3): δ 155.6, 153.2, 149.7, 147.3, 147.0, 142.9, 142.4, 140.8,

130.7, 130.1, 127.9, 127.0, 123.7, 119.4, 118.6, 114.8, 114.7, 113.7, 111.7, 88.0, 72.2,
59.3, 57.2, 46.8, 46.2, 43.3, 43.1, 41.0, 37.8, 35.7, 31.8, 30.8, 30.7, 28.4, 23.9, 22.8, 20.7,
19.9, 14.4, 14.3 ppm; LC-MS: (M+H)+ 640.4 m/z; HRMS: calcd. for C40H49NO6 (M+) m/z
639.3559, found m/z 639.3558.

MeO
N

O
O
OH

O

H
O

Codeine-abn-Cannabidiol Carbonate Codrug. abn-Cannabidiol (0.17 g, 0.54
mmol) was placed in a round bottom flask under a nitrogen atmosphere and was
dissolved in 3 mL of dry THF. The solution was cooled to 0 °C. NaH (0.024 g, 0.70
mmol) was added to the solution and allowed to stir for 5 min. Codeine-p-nitrophenol
carbonate (0.251 g, 0.55 mmol), dissolved in 3 mL of dry THF was added to the reaction
mixture drop-wise and the reaction mixture was allowed to warm to ambient temperature.
The progress of the reaction was monitored by TLC. After the completion of the reaction,
the mixture was filtered through a pad of celite and concentrated under reduced pressure.
Obtained residue was dissolved in methylene chloride (25 mL), washed with 50% sodium
bicarbonate solution (3 x 15 mL), water (15 mL), and brine (10 mL), dried and
concentrated under reduced pressure to afford the crude solid. The crude mixture was
subjected to silica gel column using a methylene chloride/methanol gradient to afford a
pure product (0.13 g, 39%). 1H NMR (500 MHz, CDCl3): δ 6.68 (1H, d), 6.59-6.55 (3H,
m), 6.15 (1H, s), 5.77 (1H, d), 5.50 (1H, br s), 5.43 (1H, d), 5.20 (1H, d), 5.11 (1H, m),
4.62 (1H, d), 4.32 (1H, s), 3.87 (3H, s), 3.57 (1H, dm), 3.05 (1H, d), 2.63-1.22 (29H, m),
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0.87 (3H, t) ppm;

13

C NMR (500 MHz, CDCl3): δ 155.03, 153.4, 150.6, 148.9, 146.6,

144.4, 142.5, 133.6, 130.9, 129.4, 128.2, 126.4, 126.3, 127.7, 119.7, 116.2, 115.4, 110.9,
109.2, 87.3, 71.1, 59.3, 57.6, 46.9, 45.0, 43.0, 41.8, 40.6, 39.9, 34.9, 34.1, 32.1, 31.1,
30.3, 28.9, 23.5, 22.7, 21.3, 20.4, 14.3 ppm; LC-MS: (M+H)+ 640.4 m/z; HRMS: calcd.
for C40H49NO6 (M+) m/z 639.3559, found m/z 639.3543.

Synthesis of 3-O-acetylmorphine-∆9-tetrahydrocannabinol Codrug.

O
O

N

O

H
HO

3-O-Acetylmorphine. Morphine free base (1.102 g, 3.87 mmol) was suspended
in saturated sodium bicarbonate solution (55 mL). To the stirred suspension, 1.1 mL
(11.68 mmol) of acetic anhydride was added drop-wise. Reaction mixture was stirred at
ambient temperature and the progress of the reaction was monitored by running TLC.
After the completion of the reaction, aqueous phase was extracted with chloroform (5 x
20 mL), dried over sodium sulfate and concentrated under reduced pressure to afford a
white solid product (1.21 g, 96%). 1H NMR (300 MHz, CDCl3): δ 6.73 (1H, d), 6.60 (1H,
d), 5.74 (1H, dd), 5.27 (1H, dd), 4.92 (1H, m), 4.16 (1H, m), 3.38 (1H, m), 3.06 (1H, d),
2.60 (1H, m), 2.54 (1H, dd), 2.43 (3H, s), 2.37 (1H, dt), 2.32 (3H, s), 2.29 (1H, dd), 2.05
(1H, dt), 1.88 (1H, d) ppm; 13C NMR (300 MHz, CDCl3): δ 168.6, 148.7, 134.2, 132.7,
132.3, 131.7, 127.8, 121.1, 119.8, 92.5, 66.0, 59.1, 46.0, 43.3, 42.3, 41.6, 35.4, 21.4, 20.9
ppm; MS (ESI): (M+1) 328 m/z.
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3-O-Acetylmorphine-p-nitrophenol Carbonate. 3-O-Acetylmorphine (2.0 g,
6.12 mmol) was placed in a round bottom flask under a nitrogen atmosphere and was
dissolved in dry chloroform (10 mL). The solution was cooled to 0 °C. DMAP (0.9 g,
7.34 mmol) was added to the solution and allowed to stir for 5 min. pNitrophenylchloroformate (1.48 g, 7.34 mmol) dissolved in dry chloroform (8 mL) was
added to the reaction mixture drop-wise and the reaction mixture was stirred at 0 °C.
Progress of the reaction was monitored by running TLC. After the completion of the
reaction, the mixture was diluted with chloroform (20 mL). The chloroform layer was
washed 5 times with 25 mL 50% NaHCO3 solution and with brine (20 mL), dried over
anhydrous sodium sulfate and concentrated under reduced pressure to afford a solid
product (1.35 g, 45 %). 1H NMR (300 MHz, CDCl3): δ 8.30 (2H, dd), 7.51 (2H, dd), 6.82
(1H, d), 6.64 (1H, d), 5.71 (1H, dd), 5.58 (1H, dd), 5.24 (1H, m), 5.19 (1H, m), 3.42 (1H,
m), 3.09 (1H, d), 2.80 (1H, m), 2.62 (1H, dd), 2.45 (3H, s), 2.41 (1H, dt), 2.19 (3H, s),
2.09 (1H, dt), 1.92 (1H, d) ppm;

13

C NMR (300 MHz, CDCl3): δ 168.5, 155.9, 151.8,

149.2, 145.6, 132.2, 131.9, 130.4, 127.8, 126.4, 125.5, 122.3, 122.2, 121.8, 119.9, 113.8,
88.2, 72.6, 59.1, 46.7, 43.8, 42.9, 40.7, 35.3, 21.0, 20.8 ppm; MS (ESI): (M+1) 493 m/z.
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3-O-Acetylmorphine-∆9-Tetrahydrocannabinol Carbonate Codrug. ∆9-THC
(0.053 g, 0.17 mmol) was placed in a round bottom flask under a nitrogen atmosphere
and was then dissolved in 2 mL of dry THF. The solution was cooled to 0 °C. NaH (0.09
g, 0.22 mmol) was added to the solution and allowed to stir for 5 min. 3-OAcetylmorphine-p-nitrophenol carbonate (0.083 g, 0.17 mmol), dissolved in 3 mL of dry
THF was added to the reaction mixture drop-wise and the reaction mixture was allowed
to warm to the ambient temperature. The progress of the reaction was monitored by TLC.
After the completion of the reaction, the mixture was filtered through a pad of celite and
concentrated under reduced pressure. Obtained residue was dissolved in methylene
chloride (20 mL), washed with 50% sodium bicarbonate solution (3 x 10 mL), water (10
mL), and brine (10 mL), dried and concentrated under reduced pressure to afford the
crude solid. The crude mixture was subjected to silica gel column using a methylene
chloride/methanol gradient to afford a pure product (0.057 g, 51%). 1H NMR (500 MHz,
CDCl3): δ 6.81 (1H, d), 6.61 (1H, d), 6.59 (1H, d), 6.55 (1H, d), 6.07 (1H, br s), 5.75 (1H,
d), 5.47 (1H, dt), 5.22 (1H, d), 5.13 (1H, m), 3.40 (1H, m), 3.19 (1H, d), 3.09 (1H, d),
2.75 (1H, m), 2.60 (1H, dd), 2.52 (2H, t), 2.45 (3H, s), 2.39 (1H, dt), 2.32-1.66 (11H, m),
1.65 (3H, s), 1.59 (2H, m), 1.42 (3H, s), 1.32 (4H, m), 1.11 (3H, s), 0.89 (3H, t) ppm; 13C
NMR (500 MHz, CDCl3): δ 168.7, 154.7, 152.9, 149.9, 143.0, 135.1, 132.4, 132.2, 131.6,
130.1, 123.2, 123.1, 122.3, 119.6, 115.6, 115.1, 113.9, 113.7, 88.7, 72.2, 59.1, 45.6, 43.3,
43.2, 41.1, 40.9, 35.6, 35.5, 34.3, 34.2, 31.7, 31.3, 30.7, 27.7, 25.1, 23.5, 22.7, 20.9, 20.8,
19.5, 14.3 ppm; MS (ESI): (M+1) 668 m/z; HRMS: calcd. for C41H49NO7 (M+) m/z
667.3508, found m/z 667.3508.
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Chapter 3
The Analgesic activities of Codrugs and their Parent Compounds

3.1 Introduction

It is easier to design and synthesize more efficient pain modulating drugs if the
type of pain can be better understood. Pain can arise from tissue damage (nociceptive) or
from injury to the nervous system (neuropathic). Nociception refers to a withdrawal
behavior in response to a dangerous (e.g. sharp or hot) environmental stimulus (Joshi and
Honore, 2006). Nociceptive pain occurs when the nociceptive system gets activated by
noxious stimuli that can cause mechanically-, chemically-, or thermally-induced damage
to tissues (Woolf, 2004; Woolf and Salter, 2000). The nociceptive system originates in
peripheral tissues, spans the spinal cord, traverses the brain stem and thalamus, and
terminates in the cerebral cortex, where the sensation of pain is perceived. Peripheral
tissues are innervated by nociceptors, highly specialized primary sensory neurons, which
contain specific receptors or ion channels at their peripheral terminals (Woolf, 2004;
Woolf and Salter, 2000). The A-delta fiber and the C-fiber nociceptors are the two main
classes of nociceptors. C-fibers are the most common; about 70% of all nociceptors are of
the C-fiber type. Activation of these receptors or ion channels by noxious stimuli
generates a depolarizing current (or an action potential, or an electrical impulse), which is
then relayed to the brain for pain perception (Fig. 3.1) (Scholz and Woolf, 2002). This
pain is well localized, and is characterized as dull or aching.

The A-delta fiber and the C-fiber nociceptors are the 2 main classes of
nociceptors. C-fibers are the most common; about 70% of all nociceptors are of the Cfiber type.
Neuropathic pain arises from injury to, or abnormal function of the nervous
system. The pain can occur even without any physical or chemical stimuli. Unlike
nociceptive pain, neuropathic pain can persist for a long time, even after the initiating
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injury has been completely healed. This leads to abnormal processing of sensory
information by the nervous system. After the nerve injury, changes occurring in the
central nervous system can persist indefinitely. Examples of neuropathic pain are:
phantom limb syndrome, diabetic pain, shingles, herpes zoster, pain associated with HIV
infections, and pain experienced after chemotherapy. The pain is felt in many different
ways, such as burning, tingling, prickling, shooting, and spasm (Rotha et al., 1998).
Allodynia and hyperalgesia are two hallmarks of neuropathic pain. Allodynia refers to
pain due to a stimulus, which does not normally provoke pain e.g., touch, cold, light
pressure can be felt as pain. Hyperalgesia refers to an increased response to a stimulus,
which is normally painful.

Fig. 3.1 Nociceptive pain transmission (Rotha et al., 1998; Reprinted by
permission)

Different animal pain models are used for different kinds of pain. For example
models developed to measure responses to acute noxious thermal stimuli use a noxious
heat or cold stimulus to the paw or tail of rodents. These models are widely used for
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testing opioid analgesics. In these methods, latency to behavioral response is recorded
and a cut-off time period is set to avoid any tissue damage to the animal. In the tail-flick
test, an intense beam of light is applied to the tail of a rat and the latency period is
measured until the tail is flicked out of the path of the light beam (Fig. 3.2). One other
assay to determine sensitivity to heat in normal animals, as well as in animals under
chronic pain conditions, has been described by Hargreaves et al. and uses a radiant heat
source. In this method, the temperature of the heat source is applied to the hind paw and
increases over time until it reaches a painful threshold. Latency to of pain to the hind paw
is recorded and analyzed. One widely used method to test for reactivity to cold is the
application of a drop of cold acetone onto the skin of a rat. Acetone produces a distinct
kind of sensation when it evaporates. Normal rats do not respond to this stimulus, while
nerve-injured rats show an exaggerated response.

Fig. 3.2 The Tail-Flick test (Reprinted by permission)
Responses to acute noxious mechanical stimuli are measured by stimulating the
paw or the tail of rodents. In the Randall Selitto test, increased pressure is applied to the
dorsal surface of the hind paw/tail of a rat via a dome-shaped plastic tip. The threshold
(in grams) for either paw or tail withdrawal is then recorded. Similarly, responses to
acute noxious chemical stimuli can be measured by injecting chemical irritants such as
capsaicin, formalin or mustard oil. The animal responds by biting or licking the injected
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paw. These observations are recorded at various time points after administration of the
drug to be tested.
Different models are used for pain following injury to the nervous system. For
example, the chronic constriction injury pain model (Bennett’s model). This pain model
involves the tying of four loose ligatures around the sciatic nerve of a rat, just tightly
enough to touch the nerve (Fig. 3.3) (Expert Rev Proteomics, 2008, Expert Review Ltd.).
Subsequent swelling of the nerve constricts the nerve, which develops hyperalgesia and
allodynia over 10 to 14 days (Hogon, 2002).

Fig. 3.3 The Chronic Constriction Injury pain model showing tying of four loose ligatures
around the sciatic nerve (Expert Rev Proteomics, 2008, Expert Review Ltd., reprinted by
permission)
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One other most studied neuropathic pain model is L5-L6 spinal nerve ligation
(SNL; Chung’s model). In this ligation process, the L5 and L6 spinal nerves of the animal
are isolated and tightly ligated with silk thread. This induces mechanical allodynia within
7-10 days. Models have also been developed involving cold allodynia and thermal
hyperalgesia. Animals exhibit a dynamic mechanical allodynia, which is assessed by
gently brushing with a soft brush. In the present chapter, the tail-flick test is used to
assess the affect of codrugs on nociceptive pain and the chronic constriction injury pain
model is used to assess the effect of codrugs on neuropathic pain.

Codeine is a well known opioid drug commonly used to control pain, whether
alone or in combination with an adjunct drug. It produces full efficacy in the tail-flick test
for antinociception. Unfortunately, long term use of these types of drugs results in the
development of tolerance and physical dependence. This reduces the analgesic effects
necessitating the administration of high and potentially harmful doses to achieve effective
pain control. The efficacies of physical mixtures of opioids non-antinociceptive doses of
cannabinoids have been previously been characterized in rodent models of nociceptive
and neuropathic pain (Smith et al., 1998; Cichewicz et al; 2002). These models included
acute thermal nociception and peripheral neuropathy (chronic constriction nerve injury,
CCI). In the present chapter, we have investigated codrug therapy where two drugs,
codeine and Δ9-THC are administered as a single chemical entity, whereby the two
molecules are covalently linked together via a carbonate ester linkage (Cod-THC). The
efficacies of each of the parent drugs as well as a 1:1 physical mixture of the parent
drugs, codeine and Δ9-THC were compared with the Cod-THC codrug as pain
modulators in the above pain models to determine their relative effectiveness. Similarly, a
codeine-cannabidiol (Cod-CBD) codrug was also assessed for its analgesic activity and
this activity compared to the individual parent drugs.
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3.2 Methods and Materials

3.2.1 Animals

Male Sprague-Dawley rats (Harlan, Indianapolis) about 90 days old, weighing
300-350 g were used for all experiments. Rats were housed separately in a transparent
cage; with free access to standard laboratory chow and tap water in a humidity- and
temperature-controlled facility with lights on between 0600 and 1800 h. Rats were
trained in the test situation before initiation of the experimental procedures. Rats were
fasted overnight before oral administration of drug. Body weights were determined on the
day of experimentation. At the end of the experiment, rats were euthanized with
pentobarbital sodium (150 mg/kg, intraperitoneal, IP). A crossover paradigm was used
within an experiment (if possible) to minimize the number of rats. All testing was
performed in accordance with the guidelines of the National Institute of Health Guide for
Care and Use of Laboratory Animals (Publication No. 85-23, revised 1985). The protocol
was approved by the University of Kentucky Animal Care and Use Committee.

3.2.2 Drugs

The Cod-THC codrug was evaluated using tail-flick and chronic constriction
injury pain model. The parent drugs codeine, Δ9-THC and 1:1 physical mixture of
codeine and Δ9-THC were also assessed using the same pain models. Similarly, CodCBD codrug, codeine and cannabidiol parent drugs were evaluated using tail-flick pain
model. Drugs were dissolved in 15% PEG saline solution and administered by the oral
route using a gavage feeding needle after overnight fasting of the animals. A 15%
solution of PEG in saline (vehicle) served as the control.

3.2.3 Tail Flick test (Measure of analgesia/antinociception)

The tail-flick test primarily assesses the spinal antinociceptive (pain relief)
response to noxious thermal stimuli (D’Amour and Smith, 1941). An intense beam of
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light is applied to the tail of a Sprague-Dawley rat and the latency period is measured
until the tail is flicked out of the path of the light beam (Fig. 3.2). Baseline tail-flick
latencies were determined prior to drug administration using the tail-flick latency test.
During testing, a cutoff time of 10 s was employed to prevent damage to the tail of the
rat.

First, rats (6/group) were treated with codeine alone (10 mg/kg), and then with the
Cod-THC codrug (10 mg/kg). Drugs were administered via the oral route. Tail flick
latencies (TFL) were measured before and after the drug was given. The latency period is
the time from onset of stimulation to a rapid flick/withdrawl of the tail from heat source.
This time period is also measured before the drug is given to ensure the analgesic effect.
Therefore, responsiveness (TFL) was measured prior to (5, 10, 15, and 30 min. apart) and
at after oral dosing (Fig. 3.4). Only one dose of codrug was initially examined to confirm
the presence of an analgesic action of the codrug. This effect of a single dose of the CodTHC codrug was compared with the parent drug codeine, to compare the relative
analgesic effects of these two drugs.

Second, rats (6/group) were treated with codeine alone (10 mg/kg), and with three
doses (5, 10 and 20 mg/kg) of the Cod-THC codrug. Drugs were administered via the
oral route. Animals were tested for tail-flick response using the tail-flick apparatus.
Intensity of the heat source was adjusted to produce tail-flick latencies of 3 to 4 sec.
These baseline latencies of the rats were recorded three times (5, 10, 15, 30 min apart).
Responsiveness (TFL) was measured thrice again after oral dosing (5, 10, 15, 30 min
apart). Dose response curves can be generated if minimum of three doses of a drug are
utilized in this assay. The time-response graphs obtained with the three different doses of
codeine-THC codrug are illustrated in Fig. 3.5 and are compared with that of the 10
mg/kg codeine dose.

Third, rats (6/group) were treated with three doses (5, 10 and 20 mg/kg) of
codeine administered via the oral route. Responsiveness (TFL) was measured prior to
(baseline) and thrice (5, 10, 15, 30 min. apart) after oral dosing as described earlier.
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Time-response and dose-response curves were drawn to calculate ED50 values for both
codeine and the Cod-THC codrug (Fig. 3.7).

In a similar manner, the codeine-cannabidiol codrug (Cod-CBD) and its parent
drugs codeine and cannabidiol were assessed in the tail-flick test. Rats (6/group) were
treated with codeine alone (10 mg/kg), with cannabidiol alone (10 mg/kg) and with three
doses (5, 10 and 20 mg/kg) of Cod-CBD codrug (Fig. 3.14).

3.2.4 Chronic Constriction nerve injury (CCI, Neuropathic pain model)

Surgery

The rodent model of peripheral neuropathy (chronic constriction nerve injury,
CCI) (Bennett and Xie, 1988) was used to characterize the antihyperalgesic effect of
codeine and with the codeine-Δ9-THC codrug. This pain model involves the tying of four
loose ligatures around the sciatic nerve, which results in the development of mechanical
(tactile) allodynia in the ipsilateral hindpaw of the rat.

Mechanical hyperalgesia

Enhanced sensitivity to mechanical noxious stimuli (mechanical hyperalgesia)
was evaluated using the paw pressure test (Randall and Selitto, 1957). This was done
prior to surgery (pre-CCI baseline) and on the post-surgery day. The hind paw was placed
between a blunt pointer and a flat surface and increasing pressure was applied to the
dorsal side of the paw. Rats (6/group) were treated with codeine alone (4.9, 10, 20, 40
mg/kg doses), Δ9-THC alone (5.1 mg/kg dose) and Cod-THC codrug (2.5, 5 and 10
mg/kg doses). Drugs were administered via the oral route.

3.2.5 Statistical analysis
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Responses were normalized for baseline values. Percent maximum possible effect
was calculated at the time of peak response: %MPE = (TFL-baseline)/ (cut-off-baseline)
* 100. ED50 values were computed for Cod-THC codrug and codeine. The overall effects
(antihyperalgesia) were presented as areas-under-the-time curves, calculated by the
trapezoidal rule for baseline normalized responses. Data were analyzed using regression
analysis, analysis of variance (ANOVA), post-hoc Student Newman Keuls test (SNK)
and t-test. Level of significance was P≤0.05. All data were mean ± SEM (n = number of
rats).

3.3 Results

3.3.1 Cod-THC codrug antinociception (tail flick tests)

The antinociceptive effects of codeine alone and various doses of Cod-THC
codrug were characterized after the oral administration in the tail-flick test. The present
data provides evidence (Figs. 3.4, 3.5, 3.6, 3.7, 3.8) that a codrug consisting of codeine
(low dose) and Δ9-THC (non-effective dose) significantly enhances codeine effectiveness
against acute nociception. In preliminary experiments, one dose of Cod-THC codrug and
one dose of codeine were given to the rats to check and compare the analgesic effect of
the Cod-THC codrug with codeine. A 10 mg/kg dose of Cod-THC codrug and a 10
mg/kg codeine dose were chosen for this purpose (Fig. 3.4). Codeine and Cod-THC
codrug tail-flick latency values were above baseline values, which indicate that both
drugs exhibit an analgesic effect. On comparing the effect of codeine with the Cod-THC
codrug, it can be observed that the analgesic effect of the codrug is much greater than that
of codeine. Next, the time-response curve for three doses of the Cod-THC codrug (5, 10,
20 mg/kg) was generated to obtain a dose-response curve. Figs. 3.5 and 3.6 illustrate the
time-response curve for the 5, 10, 20 mg/kg doses. In Fig. 3.5, the three doses of CodTHC codrug were compared with codeine (10mg/kg) and in Fig. 3.6 the time-response
curve for the three doses of the Cod-THC codrug is shown. Table 3.1 reports the areaunder-the-curve (AUC) values for all the three doses of the Cod-THC codrug.
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It can be seen that as the dose of the Cod-THC codrug is increased, the AUC also
increases. This indicates that the drug exhibits a dose-response curve (Dose: F5,23= 11.1,
P<0.0005). F5,23= 11.1 indicates that the codrug is exhibiting a dose-response effect and
the P<0.0005 value proves the statistical significance of the data between each increasing
dose. Post-hoc Student Newman Keuls (SNK) analysis indicates that the 10 and 20 mg/kg
dose showed a significant analgesic effect when compared to vehicle alone (P<0.05). The
maximum analgesic effect was observed after 15 minutes with the 10 mg/kg dose, and
after two hours with the 20 mg/kg dose of the Cod-THC codrug. This unusual result
could be due to a solubility issue with the higher dose of codrug in the vehicle. The drug
may be precipitating out in the gastrointestinal tract, probably in the stomach, after oral
administration and then slowly dissolves as it passes through the gastrointestinal tract.

Fig. 3.4 Tail-Flick Latencies for Codeine and Cod-THC Codrug
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Fig. 3.5 Antinociceptive Effect of Codeine and Cod-THC Codrug (5, 10, 20 mg/kg doses)
in the Tail-Flick Pain Model
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Fig. 3.6 Time-response Curves for the Cod-THC Codrug in theTail-Flick Test
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(a)

(b)

Fig. 3.7 Time-response (a) and dose-response (b) curves for Codeine in the Tail-Flick
Model
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Table 3.1 AUCs for 5, 10, and 20 mg/kg doses of Cod-THC Codrug

Cod-THC Codrug dose

AUC0-240 min. (s * min)

5 mg/kg

190.5 ± 34.9

10 mg/kg

747.6 ± 144.6

20 mg/kg

1025 ± 171.1

Vehicle

8.5 ± 1.7

Fig. 3.8 illustrates the %MPE (Maximum Possible Effect) for the Cod-THC
codrug and for codeine. % MPE can be related to the effectiveness of the drug. The
greater the %MPE, the more effective the drug is. The highest %MPE achieved by
codeine and the Cod-THC codrug is 70%. Increasing the dose further for both codeine
and the Cod-THC codrug does not result in a further increase in the %MPE. The 20
mg/kg dose of the Cod-THC codrug produced the highest %MPE. The equi-effective
dose of codeine was 40 mg/kg compared to a 20 mg/kg dose of the Cod-THC codrug.
The 20 mg/kg dose of the Cod-THC codrug contains 9.8 mg/kg dose of codeine.
Therefore, the analgesic effect shown by 9.8 mg/kg dose of codeine when given in the
form of the Cod-THC codrug is equivalent to a 40 mg/kg dose of codeine alone. In
conclusion, the present data demonstrates that combining codeine with Δ9-THC in the
form of a codrug may enhance codeine effectiveness against acute nociception by
decreasing the side effects associated with higher doses of codeine.
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Fig. 3.8 Dose-Response Curves for the Antinociceptive Effects of the Codeine-THC
Codrug and Codeine Alone in the Tail-Flick Test

3.3.2 Cod-THC codrug Antihyperalgesic effect (CCI model)

Chronic constriction nerve injury (CCI) results in significantly decreased
thresholds to mechanical noxious stimuli (hyperalgesia) compared to the pre-surgical
threshold. The paw withdrawal threshold (PWT) (pre-CCI) was 225 ± 3.5 g versus a
PWT (post-CCI) of 112 ± 4.3 g. The antihyperalgesic effect of codeine alone, Δ9-THC
alone and various doses of the Cod-THC codrug were characterized after administration
via the oral route. The data obtained provides evidence (Figs. 3.9, 3.10, 3.11, 3.12, 3.13)
that the Cod-THC codrug exhibits a synergistic antihyperalgesic effect. Fig. 3.9
92

demonstrates the time-response and dose-response curves for various doses of codeine
alone (4.9, 10, 20, 40 mg/kg). Dose-response curves for codeine were generated to
determine the dose of codeine that was equi-effective as the Cod-THC codrug. 65%MPE
was exhibited by codeine. Figs. 3.10 and 3.11 show the time-response curves for various
doses of the Cod-THC codrug (Dose: F5,23= 6.8, P<0.005). F5,23= 6.8 indicates that the
codrug is exhibiting a dose-response effect and the P<0.005 value proves the statistical
significance of the data. Post-hoc Student Newman Keuls (SNK) analysis indicates that
the 5 and 10 mg/kg doses of the codrug showed an enhanced antihyperalgesic effect
when compared to vehicle alone. The maximum possible effect was achieved around 1.7
hours post-dosing with the 5 mg/kg dose of the Cod-THC codrug, and at 3.5 hours postdosing with the 20 mg/kg codrug dose. The enhancement of the analgesic response is
evident at several points in the time-response curves, as well as in the overall effect
(AUC) (Table 3.2).

The bar graph illustrated in Figs. 3.12, 3.13 indicate that the antihyperalgesic
effect of the Cod-THC codrug is much more than just an additive effect of the two parent
drugs. Both codeine and Δ9-THC at doses (4.9 mg/kg and 5.1 mg/kg) that did not produce
a significant effects of their own, afforded an enhanced antihyperalgesic effect when each
drug was incorporated into the Cod-THC codrug in their molar amounts(10 mg/kg CodTHC codrug) (Fig. 3.11). One must consider the benefits of a synergistic relationship
over an additive interaction. Additivity simply represents the addition of the expected
effects of each dose of drug alone, whereas synergy describes a situation in which the
combined effect greatly exceeds the expected simple addition. Clearly, synergistic drug
interactions would be more significant, indicating that low doses of two drugs covalently
tethered together in a codrug molecule could produce effects of high magnitude. The
clinical benefits of such an enhancement can be easily imagined, as it would allow for the
administration of much lower drug doses, which would still yield a potent analgesic
effect yet hopefully induce fewer side effects. This is the first report of a synergistic
interaction between Δ9-THC and codeine after administration of a Cod-THC codrug,
since previous studies have only examined the physical mixtures of these two drugs.
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(a)

Fig. 3.9 (a)Time-response curve for Codeine in the CCI model
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(b)

Fig. 3.9 (b) Dose-response curve for Codeine in the CCI model
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Fig. 3.10 Antihyperalgesic effect of the Cod-THC codrug in the CCI Model
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Fig. 3.11 Time-Action Curves for the Cod-THC Codrug in the Chronic Constriction
Nerve Injury (CCI) Model

Fig. 3.12 Antihyperalgesic Effect of the Cod-THC Codrug in the Chronic Constrictive
Nerve Injury (CCI) Model
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Table 3.2 AUCs for 2.5, 5, and 10 mg/kg Cod-THC Codrug (CCI model)

Cod-THC Codrug dose (mg/kg)

AUC0-180 min. (g * min)

2.5
5
10

1925 ± 808.7
6406.3 ± 1663.9
9387.5 ± 2384.8
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3.3.3 ED50 values

The dose of a drug that is pharmacologically effective for 50% of the population
exposed to the drug, or that shows a 50% response in a biological system that is exposed
to the drug is defined as the ED50 value of the drug. As can be seen in Table 3.3, the ED50
value for the Cod-THC codrug in the Tail-flick test, as well as in the CCI pain model is
much lower than the ED50 value of codeine in either test, which suggests that the use of a
low dose combination of these two analgesics in a codrug structure is a valid and
effective approach for improved treatment of pain.

Table 3.3 ED50 values for the Cod-THC codrug and codeine

MeO
Bun
O
O

H

O

MeO

N

O
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N
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O

H
HO

H

ED50 = 6.42 mg/kg(Tail-flick)

ED50 = 12.5 mg/kg (Tail-flick)

= (0.01 mmol/kg)

= 0.042 mmol/kg

= 3.99 mg/kg (CCI)

= 13.5 mg/kg (CCI)

=(0.0062 mmol/kg)

=(0.045 mmol/kg)
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3.3.4 Codeine-cannabidiol (Cod-CBD) codrug antinociception (tail flick test)

The antinociceptive effects of codeine alone (10 mg/kg), cannabidiol alone (10
mg/kg) and various doses of the Cod-CBD codrug (5, 10 and 20 mg/kg) were evaluated
after oral administration in the Tail-flick test (Fig. 3.14, 3.15). Cannabidiol was chosen
because it is a non-psychoactive cannabinoid. Fig. 3.14 shows the dose-response curve
for the antinociceptive effect of the Cod-CBD codrug. The graph illustrates that 10 and
20 mg/kg doses of the Cod-CBD codrug exhibit an antinociceptive effect. A 10 mg/kg
dose of codeine shows 30 %MPE, while a10 mg/kg dose of cannabidiol shows 40 %MPE
in the Tail-flick test. When given in the form of the Cod-CBD codrug, the %MPE
produced by the 20 mg/kg dose is 70 %. This is an example of additive effect rather than
synergistic effect (Fig. 3.15). The opioid dose can still be reduced even with the additive
effect shown by the Cod-CBD codrug since less codeine is needed to show the same
effect when given in conjugation with cannabidiol.
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Chapter 4
In-vitro Stability Study of the Cod-THC Codrug
4.1 Introduction

Compounds in drug discovery encounter a wide range of pHs when administered
to patients. Oral dosing exposes compounds to pH 1 to 2 in the stomach, pH 4.5 at the
beginning of the small intestine, pH 6.6 as an average pH for the small intestine, and pH
5 to 9 in the colon. The mean fasting stomach pH of an adult is approximately 2, and
increases to 4-5 following ingestion of food. These are useful pHs for in vitro evaluation
of the chemical stability of a drug candidate as it passes through the gastrointestinal tract
(Kern and Di 2008).

Important insights can be obtained by studying the stability of the drug with
simulated gastrointestinal fluids. These include simulated gastric fluid (SGF) and
simulated intestinal fluid (SIF) (Piper et al., 1963; DeBeer et al., 1935). The recipe of
preparing these gastrointestinal fluids are specified in the United States Pharmacopeia
(USP) and described in chapter 1. The prime object of performing stability study of a
drug in nonenzymatic and enzymatic assays is to predict stability of the drug in
gastrointestinal tract after oral dosing. The obtained stability results can guide the
structural modification of the drug to improve gastrointestinal stability for increasing
bioavailability and

for prioritization of compounds

for subsequent

in vivo

pharmacokinetic studies (Patrick, 1995).

Blood contains a large number of hydrolytic enzymes such as cholinesterase,
aldolase, lipase, dehydropeptidase, and alkaline and acid phosphatase. If the drug has a
labile moiety, sensitive to one of these enzymes, it can be decomposed in the plasma.
Many such enzyme sensitive groups are used to enhance the compound’s
pharmacological activity at the target protein. Rapid hydrolysis in plasma can be a major
cause of a compound’s rapid clearance, and pharmacologically efficacious concentrations

102

may not be achievable in vivo if this occurs. Exceptions are the issue of a prodrug or a
codrug, which requires hydrolysis in plasma to produce the active parent drug(s). Prodrug
strategy is mainly utilized to improve absorption of the prodrug from the gastrointestinal
tract, since the prodrug will be designed to enhance gastrointestinal absorption by
improvement on physicochemical properties compared to the parent drug. Similarly in a
codrug strategy gastrointestinal absorption of the two parent drugs can be improved.
Once in the plasma, the codrug is designed to be rapidly hydrolyzed to afford the parent
compounds. Therefore, before the in vivo study of the codrug is performed, plasma
stability data must be generated to determine if the codrug is stable in the gastrointestinal
tract (Kern and Di 2008).

With the aim of improving the oral bioavailability of the parent drugs codeine and
Δ9-THC, the codrug Cod-THC was initially evaluated for its stability in buffers ranging
from pH 1 to pH 9 (Waterman et al., 2002), as well as in SGF, SIF, and rat plasma and
brain. The following experiments were performed in aqueous solutions to model drug
barriers:
•

pH : Aqueous buffers (37 ºC, pH 1-9)

•

GI : Simulated gastric fluid (USP, 37 ºC)

•

GI : Simulated intestinal fluid (USP, 37 ºC)

•

Plasma : Rat plasma (37 ºC)

•

Brain : Brain homogenate (37 ºC)

The molecular weight of the Cod-THC codrug is 639 g/mole. Since this value is
above 500, the molecule might not cross the blood-brain barrier, but this cannot be
concluded before carrying out the pharmacokinetic study of the Cod-THC codrug. If
the codrug does cross the blood-brain barrier, then it is important to determine its
stability in brain homogenate, to determine if it can be hydrolyzed by brain enzymes
to release the parent drugs. Thus, a stability study of the Cod-THC codrug was also
carried out in rat brain homogenate.
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4.2 Materials and Methods

4.2.1 Drugs
The Cod-THC codrug and Δ9-THC were synthesized in the laboratory via the
procedures reported in Chapter 2.

4.2.2 Sample preparation

Standard curve and quality control validation solutions:
Stock solutions of Cod-Δ9-THC, codeine, Δ9-THC and the internal standard (2methoxynaphthalene) were prepared in methanol. A standard curve with eight points was
prepared and utilized in the quantitative analysis of the unknown samples. Standard curve
samples were prepared by spiking blank plasma/buffers/brain homogenate with CodTHC, Codeine, or Δ9-THC working solutions. Calibration curves were obtained using
quadratic least-squares regression of area-under-the-curve (AUC) ratios (analyte peak
AUC/internal standard peak AUC) versus drug concentrations. The amount of codrug, or
parent drugs, was then determined using the standard curves.

Kinetics of hydrolysis of the codrug in aqueous solutions (non-enzymatic):

A 0.02 M hydrochloric acid buffer, pH 1.3, as a non-enzymatic simulated gastric
fluid; a 0.02 M sodium phthalate buffer, pH 5.2; a 0.02 M phosphate buffer, pH 7.4; and
a 0.02 M boric acid and potassium chloride buffer, pH 9.7 was used in this study. The pH
5.2 simulates intestinal fluid and the pH 7.4 simulates rat plasma. pH 9.7 was utililized to
check the chemical stability of the carbonate bond present in Cod-THC codrug. Reactions
were initiated by adding 5mL of 1.0*10-3 M stock solution (in methanol) of the CodTHC codrug to 5 mL of appropriate thermostated (37 ± 0.5 oC) aqueous solutions of the
above buffer species. Aliquot-parts (300 µL) were removed from the codrug-buffer
solutions at various time intervals, mixed with 50 µL of the 0.01M internal standard
solution (2-methoxynaphathalene) and 20 µL of the resulting solution was immediately
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injected onto the HPLC-DAD analytical system for quantitative analysis. Experiments
were run in triplicate (Omar, 1998).

Kinetics of hydrolysis of the codrug in simulated gastric fluid (SGF) and simulated
intestinal fluid (SIF) (enzymatic conditions):

Reactions were initiated by adding 5mL of 1.5*10-3 M stock solution (in
methanol) of the Cod-THC codrug to 5 mL of appropriate thermostated (37 ± 0.5 oC)
SGF and SIF solutions. Aliquot-parts (300 µL) of the resulting solutions were removed at
various time intervals, mixed with 50 µL of the 0.01M internal standard solution (2methoxynaphathalene) and immediately analyzed by HPLC-DAD.

Experiments were

run in triplicate.

Kinetics of hydrolysis of the codrug in rat plasma (in vitro):

Plasma from male Sprague-Dawley rats was obtained by centrifugation of blood
samples at 12000 rpm for 10-15 min. The supernatant plasma fractions (2 mL) were
diluted with phosphate buffer to afford a total volume of 2.5 mL (80% rat plasma).
Incubations were performed at 37 ± 0.5 oC in a water-bath with constant stirring.
Reactions were initiated by adding 100 µL of the Cod-THC codrug stock solution (0.06
M in methanol) to 2.5 mL of preheated (37oC) 80% rat plasma. Aliquot-parts (100 µL)
were removed at various times, mixed with 50 µL of the 0.01M internal standard solution
(2-methoxynaphathalene in methanol) and then deproteinized by mixing with 600 µL of
acetonitrile. After centrifugation for 10 minutes at 12,000 rpm, the supernatant was
separated, dried under nitrogen gas, the residue reconstituted with 300 µL of methanol,
and the resulting solution was analyzed by HPLC-DAD.

Kinetics of hydrolysis of the codrug in rat brain homogenate:

Brain homogenate obtained from male Sprague-Dawley rats was obtained by
homogenizing brain tissues with 3 volumes of 1.15% KCl/g brain tissue for 2 minutes in
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a tissue homogenizer. Incubations were performed at 37 ± 0.5 oC in a water-bath with
constant stirring. The reactions were initiated by adding 100 µL of the codrug stock
solution (0.06 M in methanol) to 2.5 mL of preheated (37oC) brain homogenate. Aliquotparts (100 µL) were removed at various times, mixed with 50 µL of the 0.01M internal
standard solution (2-methoxynaphathalene in methanol) and deproteinized by mixing
with 600 µL of acetonitrile. After centrifugation for 10 minutes at 12,000 rpm, the
supernatant was separated, dried under nitrogen gas, the residue reconstituted with 300
µL of methanol, and the resulting solution analyzed by HPLC-DAD.

4.2.3 HPLC analysis

HPLC analysis was carried out with an Agilent 1100 series Quatpump, equipped
with a photodiode array detector and a computer integrating apparatus. A Waters
Symmetry ® C18 (5 µm, 3.9 x 150 mm) column protected with guard column (NovaPak® C18; 3.9 x 20 mm; 4µ) was used as the stationary phase; Methanol/6mM phosphate
buffer containing 0.025% heptafluorobutyric acid (HFBA) with the pH adjusted to 6.9
with triethylamine was used as mobile phase. A 1.2 mL/min flow rate was used, and UV
detection was carried out at 220 nm. The 20 min time gradient program was as follows :
0-4 min: 45% Buffer
4-7 min: 45% to 7% Buffer
7-14 min: 7% Buffer
14-17 min: 7% to 45% Buffer
17-20 min: 45% Buffer

Analytes were eluted out at 4.7 min (codeine), 6.7 min (2-methoxynaphthalene),
8.4 min (Δ9-THC), and 12.2 min (Cod-THC codrug) using a 20 min gradient time
program.

The ion-pairing agent HFBA was utilized since it afforded better resolution of
analyte peaks. Ion pairing agents are ionic compounds that contain a hydrocarbon chain
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that imparts hydrophobicity such that the resulting analyte ion pair can be better retained
on the reversed-phase column. Ion-pairing agents are added at concentrations of between
0.01 to 0.2% w/v. Hydrophobic counter-ions such as trifluoroacetate (TFA) and
heptafluorobutyrate, in addition to ion-pairing with positively charged solutes also
increase the affinity of the solute for the hydrophobic stationary phase.

4.3 Results

4.3.1 Assay Validation

The calibration curves were linear over the concentration range of 4-2500 µM for
Cod-THC, 5-2400 µM for Codeine and 1.0-2200 µM for ∆ 9-THC with r2 > 0.99 for CodTHC, codeine and ∆9-THC respectively (Fig. 4.1).
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Fig. 4.1 Standard curves for Cod-THC codrug, Δ9-THC and codeine
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4.3.2 Chemical and enzymatic stability study

Chemical and enzymatic stability studies on the Cod-THC codrug were carried
out in vitro. Chemical hydrolysis was examined utilizing buffers at pH 1.3, 5, 7.4 and 9.7,
and enzymatic hydrolysis was examined in simulated gastric fluid (SGF), simulated
intestinal fluid (SIF), rat plasma and brain homogenate. Half-life values and the rate
constant of the hydrolysis of the codrug in different media were obtained from slopes of
semi-logarithmic plots of codrug concentrations versus time.

The data from the chemical hydrolysis studies at pH 1.3 and in SGF indicates that
the Cod-THC codrug is stable in these media, and thus is not likely to undergo chemical
or enzymatic hydrolysis in the stomach when given orally. In fact, no observable
degradation of the codrug occurred in these media over 8 hours (Figs. 4.2, 4.3). Thus, the
Cod-THC codrug should pass unhydrolyzed through the stomach after oral
administration. Additionally, at pHs 5.0, 7.4 and in SIF, no degradation of the codrug was
observed for 8 hours. Thus, the codrug should be absorbed intact from the intestine and
reach the systemic circulation as a single molecular entity (Figs. 4.2, 4.3).
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Fig. 4.2 Hydrolysis of the Cod-THC codrug at different pHs (non-enzymatic hydrolysis)

109

Conc.(10-5 M)

12

SGF
SIF
Brain Homogenate
Rat Plasma

8

4

0
1

2

4

6

8

10

Time(hrs)
Fig. 4.3 Hydrolysis of the Cod-THC codrug in different enzymatic solutions

In rat plasma, significant hydrolysis of the Cod-THC codrug was observed and
the kinetics of codrug disappearance with concomittant codeine and Δ9-THC appearance
was determined by HPLC-DAD analysis. The disappearance of the Cod-THC codrug was
correlated with pseudo first order kinetics (Figs. 4.3, 4.4). The same kinetic behavior was
observed in buffer at pH 9.7 (Figs. 4.2, 4.5). Table 4.2 reports the hydrolytic rate
constants and half-life values of the codrug obtained by regression analysis from slopes
of semi-logarithmic plots of concentration versus time.

4.3.3 Stability study in brain homogenate

The stability study of the Cod-THC codrug in brain homogenate was carried out
over 8 hrs and samples were analyzed by HPLC–UV assay. The data from the enzymatic
hydrolysis study in brain homogenate indicates that the Cod-THC codrug is stable in
brain, and thus is not likely to undergo enzymatic hydrolysis in the brain. In fact, no
observable degradation of the codrug occurred over 8 hours (Fig. 4.3).
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Fig. 4.4 Hydrolysis of the Cod-THC codrug in rat plasma

Table 4.1 Rate constants for the hydrolysis of the Cod-THC codrug in pH 9.7 buffer and
o

80% Rat plasma at 37 C

t1/2 (hr)

Kobs (hr-1)

Rat plasma

2.46 ± 0.11

0.282 ± 0.012

pH 9.7

19.25 ± 1.21

0.036 ± 0.001
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Fig. 4.5 Hydrolysis of the Cod-THC codrug at pH 9.7

Results of the comprehensive stability study of the Cod-THC codrug in different
nonenzymatic aqueous buffers and biological media demonstrate that the carbonate ester
linkage of the codrug is predicted to be stable in the gastrointestinal tract when the
codrug is administered orally. Hydrolysis of the carbonate ester linkage in 80% rat
plasma showed that the codrug is hydrolysed and generates the parent drugs, suggesting
that after oral administration, and absorption from the gastrointestinal tract the codrug
will generate both parent drugs in the systemic circulation. Linker design in codrug
synthesis has to be carried out in a thoughtful way such that the linker is not too
chemically labile or too stable. Codrugs with labile linkers will not survive the harsh
conditions of the gastrointestinal tract, and thus will hydrolyze in the gastrointestinal tract
before the codrug reaches the systemic circulation. Codrugs with very stable linkers may
reach the systemic circulation, but may not be capable of generating the parent drugs in
the plasma. Thus the choice of a carbonate ester linkage linking the allylic hydroxyl
group of codeine and the phenolic group of Δ9-THC was found to be an ideal codrug
linker design for oral administration. The stability of the Cod-THC codrug in rat brain
homogenate indicates that the enzymes present in rat brain homogenate are incapable of
cleaving the codrug into the parent drugs. This study predicts that any codrug entering the
brain from the systemic circulation will not be transformed into the parent drugs. Thus, if
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oral administration of the codrug to rats results in the presence of the parent drug
molecules in brain, then these parent drugs must have entered the brain as the individual
parent drug molecules from the systemic circulation, and did not originate through
hydrolysis of the codrug in the brain.

Copyright © Harpreet Dhooper 2010
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Chapter 5
Pharmacokinetic Analysis of Cod-THC Codrug
5.1 Introduction

Pharmacokinetics is the study of the time course of a drug concentration in
different body compartments such as plasma, blood, urine, cerebrospinal fluid, and
tissues, and incorporates the processes of absorption, distribution, metabolism and
excretion (ADME) after a specific route of administration of a drug (Smith et al., 2001).
The drug can enter the body in a variety of ways which have already been
discussed in detail in Chapter 1. Drugs are mostly given orally for reasons of convenience
and patient compliance. If the drug has been given orally, then it first enters the
gastrointestinal tract, and gets absorbed through the gastrointestinal mucosal wall into the
bloodstream. It is then shunted via the portal vein through the liver, where the “first pass
effect” takes place, and then reaches the systemic circulation. The first-pass effect is a
phenomenon of drug metabolism whereby the concentration of a drug is greatly reduced
before it reaches the systemic circulation. It is the fraction of lost drug during the process
of absorption which mainly takes place in liver and gut wall. Therefore, the oral
administration of a drug involves an additional absorption step. The percentage of the
administered dose reaching the circulation as the free drug is termed the bioavailability of
the drug. The drug then gets distributed to various tissues and organs in the body. The
extent of this distribution depends on the structural and physicochemical properties of the
drug. Some drugs may enter the brain and the central nervous system by crossing the
blood–brain barrier. Finally, the drug will bind to its molecular target, for example, a
receptor or an ion channel, and exert its desired action. If the drug is injected directly into
the bloodstream (e.g. by the intravenous route), then it is 100% available for distribution
to the tissues. But if it is given orally, then its bioavailability will usually be less than
100% (Smith et al., 2001).

Once the drug is in the bloodstream, a portion of it is available to illicit its
pharmacodynamic effect; the rest may bind to plasma proteins in an inactive reversible
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protein-drug complex. Binding to plasma proteins is sometimes advantageous since the
drug is continuously released from the protein-drug complex and this can result in a
prolonged drug action (Smith et al., 2001). The unbound drug follows the concentration
gradient and gets distributed into the peripheral tissues. These tissues contain specific or
non-specific binding sites. The non-specific binding sites can act as reservoirs for the
drug. This “total volume of distribution” determines the equilibrium concentration of
drug after administration of a specific dose.

Pharmacokinetic parameters are derived from the measurement of drug
concentrations in blood or plasma after administration. The key pharmacokinetic
parameters are Volume of Distribution (Vd), Clearance (Cl), Absorption, Half-life (t1/2)
and Oral Bioavailability (F). Their importance for the dose regimen and dose size is
shown in Fig. 5.1 (van de Waterbeemd and Gifford, 2003).

Fig. 5.1 Pharmacokinetic Parameters and their importance for dose regimen and dose size
Volume of Distribution (Vd) -- Volume of Distribution is defined as the apparent
space or volume into which a drug distributes. It is a theoretical concept that connects the
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administered dose with the actual initial concentration (C0) present in the systemic
circulation. If the drug is highly lipophilic in nature, then the drug will have a high
volume of distribution, because the drug specifically or non-specifically binds to tissues
and stays there.

Vd = Dose/C0

Clearance (Cl) --Clearance of a drug from the body mainly takes place via the
liver (hepatic clearance or metabolism, and biliary excretion) and the kidney (renal
excretion).

By plotting the plasma concentration against time, the area under the curve (AUC) relates
to dose, bioavailability (F) and clearance.

AUC = F x Dose/Cl

Half-life (t1/2) --Half-life is the time taken for the drug concentration in the plasma
to be reduced by 50%. It is a function of the clearance and volume of distribution, and
determines how often a drug needs to be administered.

t1/2 = 0.693 Vd/Cl

Intravenous (IV) bolus dosing (i.e, the entire drug dose is given as a rapid
injection) captures the pure distribution and elimination processes.
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Fig. 5.2 Concentration versus time curve
In the “first pass effect” the liver metabolizes the drug into active or inactive
metabolites, which can then be more easily excreted. Prodrugs are inactive chemical
entities that get activated only after they are metabolized to the active drug. This is often
a strategy utilized to improve pharmacokinetic properties and drug ability. Some drugs
are excreted in the bile and eventually may pass out of the body in the feces, while some
are filtered by kidney, where a portion undergoes reabsorption, with the remainder being
excreted in the urine. Smaller amount of drugs are excreted in the tears, breast milk and
sweat.
5.1.1 Pharamacokinetic profile of Codeine and ∆9-THC
There is a continuing need for novel analgesic medications that are able to
provide high efficacy pain relief while providing more favorable pharmacokinetics and a
reduction in undesirable side-effects. Several reports indicate the low bioavailability (2 to
6%) of ∆9-THC after oral administration in rats due to poor absorption. ∆9-THC is also
biotransformed by the cytochrome P450 enzymes CYP 3A4, CYP 2C9 and CYP 2C11 to
11-hydroxy-∆9-THC, which contributes to its psychotropic activity, and to the 11-nor-9carboxy-THC glucuronide conjugate, an inactive major urinary metabolite (Gustafson et
al., 2004; McGilveray, 2005). Codeine is mainly metabolized in liver. Approximately 5070% of codeine is converted to codeine-6-glucuronide by UGT2B7 and approximately
10-15% of codeine is N-demethylated to norcodeine by CYP3A4 (Thorn, 2009).
Codeine-6-glucuronide also binds to the mu opioid receptor similar to codeine.
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Approximately 10-15% of codeine is N-demethylated to norcodeine by CYP3A4 (Thorn,
2009). Norcodeine and Codeine-6-glucuronide both have the affinity for the mu opioid
receptor similar to codeine. Approximately 0-15% of codeine is O-demethylated by
CYP2D6 to morphine, the most active metabolite, which has 200 fold greater affinity for
the mu opioid receptor compared to codeine (Thorn, 2009).

Enhancement of the antinociceptive effect of opioids with cannabinoids has been
previously described in literature (Cichewecz et al, 1999; Cichewecz et al, 2001;
Cichewecz and McCarthy 2002; Cichewecz and Welch 2003; Cox et al., 2007; Smith et
al., 2007; Smith et al., 1998; Welch and Eads, 1999; Williams et al., 2008)). These opioid
and cannabinoid drugs work via opioid and cannabinoid receptors, which are found
throughout the central and peripheral nervous system. In addition, these two classes of
drugs produce similar effects on calcium levels and cyclic AMP accumulation through G
protein-mediated pathways. However, appropriate combination dosing of these active
agents to afford concentrations of both drugs at the site of action, e.g., the brain or spinal
column, can be difficult because of their very different physico-chemical and
pharmacokinetic properties. Therefore, there is a need to devise a way of administering
opioids and cannabinoids concomitantly to provide a more favorable pharmacokinetic
profile that will promote optimal synergism. The analytical study of a Cod-THC Codrug
designed for this purpose has demonstrated chemical stability in gastrointestinal tract and
susceptibility to hydrolysis in rat plasma to the parent drugs, codeine and Δ9- THC
(Chapter 3). To compare the pharmacokinetic profile of the Cod-THC codrug with those
of the parent drugs (both individually and as a 1:1 physical mixture) after oral
administration physical mixture, following studies were carried out:
 To determine the pharmacokinetics of Cod-THC codrug at three different doses
(5, 10, 20 mg/kg) and to determine the pharmacokinetics codeine, and Δ9-THC
after oral administration of an equimolar physical mixture dose (4.9 mg/kg
codeine + 5.1 mg/kg Δ9-THC) of the two parent drugs in the rat.
 To evaluate the relative ability of the Cod-THC codrug (10 mg/kg dose) and a 1:1
physical mixture of codeine and Δ9 –THC (4.9 mg/kg codeine + 5.1 mg/kg Δ9118

THC) to deliver codeine and Δ9-THC to the plasma and brain after oral
administration in the rat.

5.2 Materials and Methods

5.2.1 Chemicals and reagents
The Cod-THC codrug and Δ9-THC were synthesized in the laboratory (see
Chapter 2 for details). The chemicals used in this study were of HPLC grade or
equivalent quality. Acetonitrile and potassium chloride were obtained from Thermo
Fisher Scientific (Pittsburgh, PA). Heparin sodium injection, 10,000 USP units/ml, was
purchased from Baxter Healthcare Corporation (Deerfield, IL). Nembutal sodium
(pentobarbital sodium injection, USP) was obtained from Abbott Laboratories (North
Chicago, IL).

5.2.2 Animals

All procedures involving animals were performed in compliance with the
guidelines of the University of Kentucky Institutional Animal Care and Use Committee
established by the National Institutes of Health’s Guide for the Care and Use of
Laboratory Animals (1996). Male Sprague-Dawley rats (200–250 g) were obtained from
Harlan (Indianapolis, IN) and housed two per cage with ad libitum access to food and
water in the Division of Laboratory Animal Resources at the University of Kentucky
College of Pharmacy. Body weights at the time of dosing were 300-360 g. Rats were
anesthetized with pentobarbital (40 mg/kg i.p.) and surgically implanted with jugular and
femoral vein cannulas for i.v. drug dosing and blood sampling, respectively. For the first
3 to 4 days after surgery, the rats were observed for signs of infection at the surgical sites,
yellowing of hair and hair texture, presence of blood around the eyes or nose, indications
of loss of appetite, and decreased or absent fecal activity before the start of i.v. dosing.

5.2.3 Instrumentation
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Samples were analyzed for analyte-specific (640.359 m/z to 282.261 m/z, CodTHC; 315.2 m/z to 193.1 m/z, Δ9-THC; 300.2 m/z to 215.2 m/z, codeine; 286 m/z to 201
m/z morphine) and internal standard-specific (342.4 m/z to 324.2 m/z, naltrexone)
transitions by LC/MS/MS utilizing reverse-phase chromatography and positive-mode
ionization. The instrumentation consisted of a Varian LC system (ProStar 210 pumps,
Prostar 410 autoinjector) connected through an ESI source to a Varian 1200L triple
quadrupole mass spectrometer with all components controlled by a Varian MS
Workstation version 6.42. Individual analyte-dependent ESI-(+)-MS/MS parameters were
optimized for signal intensity.

5.2.4 HPLC and mass spectrometric conditions

Individual analyte-dependent ESI-(+)-MS/MS parameters were optimized for
signal intensity. These optimized parameters were subsequently used in the analysis of
biological samples (CE = 32, 19, 20.5, 16.5, 10.2V for Cod-THC, Δ9-THC, codeine,
morphine and naltrexone, respectively). Briefly, 10 µL of the biological sample was
injected onto a guard column protected (Nova-Pak® C18; 3.9 x 20 mm; 4µ) Nova-Pak®
C18 analytical column (3.9 x 150 mm; 4 um). Analytes were eluted at 8.09 min
(morphine), 10.02 min (codeine), 10.22 min (naltrexone), 14.33 min (Cod-THC), and
21.37 min (Δ9-THC) using water: acetonitrile (82:18, containing 0.04 % HFBA) (Solvent
A): acetonitrile (Solvent B) gradient and a 0.3 mL/min flow rate. The 33 min gradient
program began with 97:3 Solvents A: B for 3 min followed by a 5.3 min linear ramp to
5:95 solvents A: B. This percentage was held constant for 14 min, and then returned to
97:3 solvents A:B over a 3 min linear ramp; it was then held at 97:3 solvents A:B for an
additional 6 min. Argon was used as a collision gas at 2.0 m Torr, and nitrogen used as a
drying gas at 300 oC. The needle voltage was 5000V, the shield voltage was 600V, and
the capillary voltage was 40V. Independent plasma and brain calibration curves for CodTHC, codeine, morphine and Δ9-THC were generated from plots of analyte concentration
and analyte: naltrexone peak area ratios.

120

5.2.5 Plasma Pharmacokinetics

Cod-THC codrug solution was prepared in 15% PEG-400 solution in saline and
filtered through a 0.2-µm filter. Groups of rats (n=3) were then injected with either 5, 10,
20 mg/kg p.o. or 1 mg/kg i.v. via the jugular vein. Doses and route of administration were
chosen on the bases of studies evaluating the analgesic effect of Cod-THC codrug. Blood
samples (0.2 mL) were obtained at 1, 5, 10, 15, 30, 45, 60, 120, 180 min after i.v. dosing
and at 15 min, 30 min, 1, 2, 4, 5, 7 and 8 hrs after oral dosing. The withdrawn blood was
replaced with heparinized saline (0.2 mL). Blood samples were centrifuged at 1200 g for
15 min, and the plasma was separarted. The separated plasma was frozen immediately on
dry-ice and stored at −80°C prior to analysis. To compare the pharmacokinetics of the
codrug with an equimolar physical mixture, 4.9 mg/kg of codeine and 5.1 mg/kg of Δ9THC were mixed together and administered orally to rats. This dose of physical mixture
was chosen based on the same molar proportion of codeine and Δ9-THC in the 10 mg/kg
codrug dose.

5.2.6 Standard Curve and Quality Control Validation Solutions
Stock solutions of Cod-THC, codeine, Δ9-THC and internal standard (naltrexone)
were prepared in methanol. Two stock solutions were prepared; one for generating the
standard curve, and a second one for quality control (QC) and method validation. A
standard curve with eight points was prepared for the analysis of unknown samples.
Standard curve samples were prepared by spiking blank plasma with Cod-THC, codeine,
or Δ9-THC working solutions. Calibration curves were obtained using quadratic leastsquares regression of AUC ratio (analyte peak AUC/internal standard peak AUC) versus
drug concentrations. The amount of codrug, or parent drug, was then determined. Three
quality control samples with different concentrations were prepared to check the
sensitivity of the instrument. The three concentrations chosen were: one towards the
higher end of the standard curve concentrations, one towards the middle, and the third
one towards the lower end of the standard curve concentrations. Standard curves for
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analyzing brain samples were constructed in a similar way using brain homogenate. In
brain homogenate, a morphine standard curve was also generated.

5.2.7 Extraction procedure
To isolate Cod-THC, codeine, and Δ9-THC from plasma or brain samples, 50 µL
of plasma/brain tissue was transferred to polypropylene tubes to which 10 µl of working
internal standard solution was added followed by vortexing for 1 min. The samples were
then centrifuged for 15 min at 8000 rpm. The supernatant was transferred into silylated
micro-serts and evaporated to dryness under nitrogen gas at 37°C. Following drying, the
residue was dissolved in 80 µl of mobile phase by vortexing for 1min; 10 µl of the
sample was then injected into the LC-MS/MS unit.

5.2.8 Brain Uptake Study

Studies were performed to determine the concentration of codrug/parent drugs
present in brain after oral doses of 10 and 20 mg/kg of Cod-THC codrug. These doses
were chosen based on their assessment in the tail-flick pain model. Cod-THC codrug
solution was prepared in 15% PEG-400 solution in saline and filtered through a 0.2-µm
filter. Noncatheterized male Sprague-Dawley rats (300-360) were assigned randomly to
one of five time points (n =3 per group) for the 10 mg/kg Cod-THC codrug dose and to
one of two time points (n=3 per group) for the 20 mg/kg dose. Individual rats were
euthanized at 0.5, 1, 1.5, 2, 2.5 hrs after p.o. administration of the 10 mg/kg Cod-THC
codrug and at 2 and 2.5 hrs after p.o. administration of the 20 mg/kg Cod-THC codrug.
The brain was quickly removed, cleaned of surrounding tissue and veins, washed,
weighed, and homogenized (3 volumes of 1.15% KCl/g brain tissue) for 2 min in a tissue
homogenizer (Bio-Homogenizer M133/1281-0; Biospec Products, Inc., Barlesville, OK).
Brain homogenate (4 ml) was mixed with an equal volume of acetonitrile and centrifuged
at 1200g and 37°C for 5 min. The supernatant was separated and evaporated to dryness
under a stream of nitrogen. The residue was reconstituted in 80 µL of HPLC mobile
phase. After decapitation, blood from the trunk of each rat at the time of euthanasia was
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also collected and centrifuged at 1200g and 37°C for 5 min to obtain matching
brain/plasma samples. The plasma samples (50 µL ml) were extracted with 6 volumes of
acetonitrile and centrifuged at 1200 g for 15 min at 37°C. The supernatant was separated
and evaporated to dryness under a stream of nitrogen, and the resulting residue was
reconstituted with 80 µL of mobile phase. The same protocol was followed for the
physical mixture of codeine and Δ9-THC. To compare with the 10 mg/kg Cod-THC
codrug dose, 4.9 mg/kg of codeine and 5.1 mg/kg of Δ9-THC was utilized as a physical
mixture. Again, the time-concentration curve for this physical mixture was generated in a
similar way to that for the codrug.

5.2.9 Assay Validation

Blank plasma samples were extracted and analyzed by reverse phase HPLC for
potential interfering peaks within the range of the retention time for Cod-THC,
codeine, morphine, Δ9-THC and the internal standard, naltrexone. The extraction
efficiency was determined by spiking Cod-THC, codeine, and Δ9-THC at concentrations
of 25 and 100 ng/ml into blank plasma, and comparing peak AUCs of the extracted and
unextracted standards at the same concentrations. This was done to find the difference
between the concentrations of extracted and unextracted samples.

5.2.10 Pharmacokinetic Analysis

The plasma pharmacokinetic parameters for the Cod-THC codrug in the rat were
determined after both p.o. and i.v. administration. Data were analyzed with a standard
noncompartmental model using the program WinNonlin Professional (version 5.2;
Pharsight Corporation, Mountain View, CA). Both Cmax and Tmax were determined. The
AUC0–t for the plasma concentration-time profile was determined using the lineartrapezoidal method (Whittaker and Robinson, 1967). AUC

0–∞

was calculated as AUC0–t

+ Ct/k, where Ct is the last measurable concentration of drug. The terminal half-life (t1/2)
was calculated by dividing 0.693 by the terminal rate constant (k) obtained from the fitted
concentration-time data.
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5.3 Results

Morphine,

codeine,

naltrexone,

Δ9-THC,

and

the

Cod-THC

codrug

chromatograms are shown in Fig. 5.3. Morphine had the lowest retention time (8.09 min)
followed by codeine (10.02 min), naltexone (10.22 min), Cod-THC (14.33 min) and Δ9THC (21.37 min).

5.3.1 Assay Validation

The calibration curves for the Cod-THC codrug were linear over the
concentration range of 0.67-343.04 ng/mL , and for codeine and Δ9-THC were linear over
the concentration range 1.45-371.2 ng/mL and 1.45-371.2 ng/mL, respectively, in rat
plasma, with correlation coefficients r2 of > 0.99 for Cod-THC, codeine and Δ9-THC
(Fig. 5.4). The LLOQ was established at 0.67, 1.45 and 1.45 ng/mL for Cod-THC codrug,
codeine and Δ9-THC, respectively.
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Fig. 5.3 Morphine, codeine, naltrexone, Cod-THC codrug and Δ9-THC Chromatograms
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(a)

(b)
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(c)
Fig. 5.4 Calibration curves for codeine (a), Δ -THC (b) and Cod-THC codrug (c) in rat
plasma
9

The calibration curves for Cod-THC, codeine, Δ9-THC and morphine were
generated in rat plasma (from trunk blood) and also in rat brain homogenate (Figs. 5.5,
5.6). At the time of the brain homogenate study, the calibration curves for plasma (from
trunk blood) were generated again to compare the concentration of the parent drugs in
brain and plasma. The calibration curves generated in brain homogenate were linear over
the concentration range 0.52-266.2 ng/mL for the Cod-THC codrug, linear over the
concentration range 0.61-312.3 ng/mL for codeine, and linear over the concentration
range 0.86-440.3 ng/mL for Δ9-THC and 6.13-196.2 ng/mL for morphine in rat plasma,
with correlation coefficients r2 > 0.99 for Cod-THC, codeine, Δ9-THC and morphine
(Fig. 5.4). Fig. 5.7 shows the three chromatograms of morphine with three different
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concentrations (3000, 300 and 3 ng/mL). The morphine peak was detectable only up to 3
ng/mL.

(a)
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(b)

(c)
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(d)
Fig. 5.5 Calibration Curves for codeine (a), Δ9-THC (b), Cod-THC codrug (c) and
morphine (d) in rat plasma (trunk plasma)

5.3.2 Dose-response curve analysis for the Cod-THC codrug in plasma samples

The mean concentration versus time profiles for 5, 10 and 20 mg/kg doses of
Cod-THC codrug after oral administration are shown in Fig. 5.8. As can be seen, in all
the three doses, the Cod-THC codrug is hydrolyzed in the plasma to release the parent
drugs. The hydrolysis is not complete, as codrug can be seen along with the parent drugs
at all time points. These data also show a prolonged release of the parent drugs from the
codrug over time. The release of the parent drugs from the codrug occurs in an equimolar
ratio. At any time point in the time course, the codrug concentration is lower than that of
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either of the parent drugs, indicating the presence of mainly parent drugs compared to
codrug.

Since the codrug is being hydrolyzed in the plasma and releasing parent drugs in
1:1 ratio, this suggests that there is likely no stable intermediate codrug fragment being
formed, and even if such an intermediate is forming, it is transient and is getting
hydrolyzed very quickly to release the parent drugs concomittently. The pharmacokinetic
parameters for Cod-THC, codeine and Δ9-THC for the 5, 10, and 20 mg/kg doses are
summarized in Table 5.1. Following oral administration of the 5 and 10 mg/kg doses of
Cod-THC codrug, plasma levels of codeine and Δ9-THC reached Cmax within 1 hr. For
the 20 mg/kg dose there was a slight plateau from 2-4 hrs. This might be due to plasma
enzyme saturation, which would decrease the rate of hydrolysis of the codrug. The data
clearly show a dose-dependent relationship, since the AUC for the codrug, as well as for
the parent drugs, increased linearly with increasing dose of codrug.

(a)
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(b)

(c)
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(d)
Fig. 5.6 Calibration Curves for codeine, Δ9-THC, Cod-THC codrug and
morphine in brain homogenate
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Fig. 5.7 Morphine peaks generated from different concentrations (3000, 300 and 3 ng/mL
from the top) using slightly different LC-MS/MS method (0.05% of HFBA was added to
both aqueous and organic solvents as compared to 0.025% in the previously described
method).
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5 mg/kg Cod-THC codrug dose

10 mg/kg Cod-THC codrug

20 mg/kg Cod-THC codrug

Fig. 5.8 Plasma concentration vs. time curve after oral administration of Cod-THC
codrug (5, 10 and 20 mg/kg doses)
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Table 5.1 (a) Pharmacokinetic parameters for the Cod-THC codrug, codeine and Δ9-THC
after 5, 10, 20 mg/kg oral dosing

Codrug
(Actual)

∆ - THC
9

Codeine

Dose

AUC
(hr* pmol/mL)

T max
(hr)

C max
(pmol/mL)

T 1/2
(hr)

5 mg/kg
10 mg/kg
20 mg/kg

90.9 ± 17.4
199.7 ± 29.3
326.5 ± 37.4

1 ± 0.1
2 ± 0.1
4 ± 0.2

14.16 ± 4.64
24.4 ± 2.96
31.95 ± 6.14

4.24 ± 0.33
4.43 ± 0.25
4.57 ± 0.39

5 mg/kg
10 mg/kg
20 mg/kg

281.7 ± 22.8
375.3 ± 18.2
474.2 ± 25.6

1 ± 0.1
1 ± 0.2
2.5 ± 0.3

39.8 ± 2.32
48.1 ± 3.18
56.4 ± 3.41

2.3 ± 0.37
4.0 ± 0.46
4.9 ± 0.44

5 mg/kg
10 mg/kg
20 mg/kg

218.0 ± 19.6
318.0 ± 23.8
374.2 ± 28.3

1 ± 0.1
1 ± 0.3
3 ± 0.2

40.46 ± 2.75
49.17 ± 3.41
57.39 ± 3. 97

2.4 ± 0.29
2.5 ± 0.38
4.1 ± 0.42

Table 5.1 (b) Calculated clearance values for the Cod-THC codrug, codeine and Δ9-THC
Clearance
(mL/min)
Cod-THC Codrug

35.3

Codeine

55.6

∆ -THC

28.5

9

5.3.3 Codrug and physical mixture data comparison after oral administration

The mean concentration versus time profile for the 10 mg/kg dose of the physical
mixture (i.e. 4.9 mg/kg codeine and 5.1 mg/kg Δ9-THC) after oral administration is
shown in Fig. 5.9. For comparison, the 10 mg/kg Cod-THC codrug graph is also
displayed in the same figure. The plasma concentrations of codeine and Δ9-THC are
much higher after codrug administration compared to the plasma concentrations of these
drugs after administration of an equimolar physical mixture. The parent drugs are clearly
released from the codrug in 1:1 ratio, while administration of the physical mixture does
not afford equimolar concentrations of codeine and Δ9-THC in plasma. This is likely due
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to the different pharmacokinetic profiles of the two parent drugs and to the different
pharmacokinetic profile of the Cod-THC codrug. The parent drugs are also present in
plasma for longer period of time after oral administration of the codrug, probably due to
the sustained release of the parent drugs from codrug in the plasma. When the
pharmacokinetic parameters of an equimolar physical mixture of codeine and Δ9-THC
were calculated and compared with that of an equimolar dose of codrug after oral
administration, a significantly higher AUC for codeine and Δ9-THC was observed from
the codrug than from the physical mixture of the parent drugs.
The oral bioavailability of codeine and Δ9-THC can be calculated from the AUC
values from the oral dose (4.9 mg/kg codeine + 5.1 mg/kg Δ9-THC) and the AUC from
the i.v. dose of the physical mixture (0.49 mg/kg codeine + 0.51 mg/kg Δ9-THC). The
calculated bioavailability for codeine was 2.9 ± 1.4 % and the bioavailability for Δ9-THC
was 3.0 ± 1.8 %.

Calculation of the oral bioavailability of the codrug is not straight-forward
because of the time-dependent hydrolysis of the codrug to the parent compounds in the
plasma. Thus, two bioavailability values for the codrug can be calculated, i.e. the “actual”
codrug bioavailability, and the “total” codrug bioavailability. The actual codrug
bioavailability is based on the amount of actual codrug present in the plasma; whereas the
total codrug bioavailability is calculated assuming no hydrolysis of the codrug has taken
place in the plasma. The total bioavailability value represents an approximation of the
total amount of the codrug entering the systemic circulation after oral dosing. The actual
codrug bioavailability was calculated to be 7.7 ± 3.8 %, and the total codrug
bioavailability was found to be 21.1 ± 7.9 %. Since the total codrug bioavailability is
much higher than the bioavailabilities of either of the parent drugs after oral
administration of the physical mixture, this shows that more of parent drugs can be
delivered orally in the form of the codrug than as a physical mixture. It should be noted
that the total codrug bioavailabilty value may be underestimated, since the clearance
parameters are not taken into account for the parent drugs (shown in Table 5.1 (b)).
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Certainly, the data clearly indicates that the codrug has a superior pharmacokinetic
profile when compared to the physical mixture of the two parent drugs.

(a)

(b)
Fig. 5.9 Physical mixture of Codeine (4.9 mg) and Δ9-THC (5.1 mg) (a); Codrug 10
mg/kg (b)
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Fig. 5.10 Concentration vs. Time profile for Cod-THC (10 mg/kg dose) (a) and Physical
mixture (Cod 4.9 mg/kg + ∆9-THC 5.1 mg/kg) (b) in brain after oral dosing
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5.3.4 Brain Uptake Study Results

After oral administration of 10 mg/kg dose of the Cod-THC codrug, brain
samples were analysed at different time points (0, 0.5, 1, 1.5, 2, and 2.5 hrs). The results
of the analysis of the brain homogenate samples showed the presence of only the parent
drugs; no codrug was present in brain at any time point measured after oral dosing of the
Cod-THC codrug.

Fig. 5.10 shows the time versus concentration profiles for the Cod-THC codrug
(10 mg/kg) and the physical mixture (4.9 mg/kg codeine and 5.1 mg/kg THC) after oral
administration. The concentration of codeine and ∆9-THC is much higher in brain after
oral administration of the Cod-THC codrug as compared to the brain concentrations of
these drugs after oral administration of the physical mixture. The concentrations of
codeine and ∆9-THC in the brain reach a maximum at two hours after oral administration;
it is important to note that tmax is same for both codeine and ∆9-THC. This correlates with
the study of the codrug in rat tail-flick pain model. In the case of the physical mixture, the
∆9-THC concentration is significantly higher than the codeine concentration in brain after
oral administration. This might be attributable to the higher plasma concentration of ∆9THC compared to codeine in plasma samples after oral administration of the physical
mixture.

Thus from the pharmacokinetic data, it can be concluded that Cod-THC codrug is
much more efficient in terms of delivering higher concentrations of the two parent drugs
in both plasma and brain when compared to the equimolar physical mixture of the two
parent drugs. This also proves that combining two drugs with different physicochemical
and pharmacokinetic profiles into a single chemical entity can improve the plasma and
brain bioavailabilities of the two parent drugs. It is also noticeable that oral
administration of the codrug produces the two parent drugs in molar ratio while the
physical mixture fails to do that.

Copyright © Harpreet Dhooper 2010
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Chapter 6
Summary
There is a continuing need for analgesic medications that are able to provide high
efficacy pain relief while providing more favorable pharmacokinetics and reducing the
possibility of undesirable side effects. Enhancement of the analgesic effect of opioids
with cannabinoids has been previously described (Cichewicz et al., 1999). These opioid
and cannabinoid drugs work via opioid and cannabinoid receptors, which are found
throughout the central and peripheral nervous system. Synergy between ∆9-THC and
opioids is well documented in the literature (Bloom and Dewey, 1978; Cichewicz and
McCarthy, 2002). In addition, these two classes of drugs produce similar effects on
calcium levels and cyclic AMP accumulation through G protein-mediated pathways.
However, appropriate dosing of these active agents to the site of action, e.g., the brain or
spinal column, can be difficult because of their differential pharmacokinetics. Therefore,
in the present dissertation, a codrug strategy is presented for orally administering opioids
and cannabinoids concomitantly to provide a more favorable pharmacokinetic and
analgesic profile than would be attainable by administering equimolar amounts of the
parent drugs as a physical mixture.

Codrugs are designed to overcome various barriers to drug formulation and
delivery, such as poor or extreme aqueous solubility, chemical instability, insufficient
absorption after oral administration, rapid pre-systemic metabolism, inadequate brain
penetration, toxicity and local irritation. The first chapter in this dissertation demonstrates
the usefulness of the codrug strategy by discussing several reported examples. The
codrug strategy is very useful when the physico-chemical and/or pharmacokinetic
properties of two synergistic drugs are not favorable for delivery as a physical mixture,
but can be improved by chemical combination of the two drugs.

A series of novel codrugs obtained by chemical conjugation of the opiate drug
codeine with ∆9-THC, cannabidiol, and abn-cannabidiol, and of the opiate prodrug 3-O-
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acetylmorphine with ∆9-THC, utilizing a carbonate linker moiety, were successfully
synthesized. Before commencing the synthetic work with the expensive opiate and
cannabinoid controlled substances, coupling reactions were initially carried out with
model compounds, or chemical mimics of the drug molecules, in order to optimize the
desired coupling chemistry. p-Nitrophenylchloroformate, which has been described in the
literature as a useful reagent for the formation of unsymmetrical carbonates and
carbamates (Anderson and McGregor, 1957) was found to be a useful reagent in these
subsequent model coupling reactions. In the current work, an opiate was initially reacted
with p-nitrophenylchloroformate to form the carbonate conjugate of the opiate and pnitrophenol. This intermediate was then reacted with different cannabinoids to form the
carbonate ester conjugate (codrug) of the opiate and the cannabinoid. In this second step,
the good leaving group property of the p-nitrophenol is advantageous in the selective
formation of the desired unsymmetrical carbonate ester.
Marketed for p.o. administration as dronabinol (Marinol®), Δ9-THC is a schedule
II drug currently used as an appetite stimulant in acquired immunodeficiency syndromewasting patients, and as an anti-emetic for cancer chemotherapy when given orally.
Although high doses of Δ9-THC are analgesic, they can be accompanied by side effects,
such as anxiety, dry mouth or euphoria/dysphoria. The opiate codeine is commonly given
p.o., primarily to ease pain. However, the continued administration of codeine can lead to
tolerance, which can ultimately reduce the analgesic effect of the drug, necessitating the
administration of high and potentially harmful doses to achieve effective pain control.
Also, high doses of codeine can have undesirable side effects such as respiratory
depression, constipation, nausea and vomiting. Given that mixtures of Δ9-THC and
codeine are synergistic in the rat tail-flick test for antinociception (Williams et al., 2006),
we hypothesized that when given in the form of codrug, the administration of codeine
and Δ9-THC would have improved pharmacokinetics that would enhance the efficacy of
codeine in managing pain. Also, since codeine shows little or no effect on neuropathic
pain, we further hypothesized that a Cod-THC codrug would also exhibit an analgesic
effect in neuropathic pain models. Thus, we investigated the effect of the Cod-THC
codrug after oral administration in nociceptive and neuropathic pain models utilizing tail142

flick and chronic constriction injury pain models in the rat. The oral efficacies of each of
the parent drugs, codeine and Δ9-THC were also compared with the Cod-THC codrug as
pain modulators in the above pain models to determine their relative effectiveness. In
both pain models, the codrug showed better effectiveness, as well as more prolonged pain
management properties, when compared to the parent drugs. ED50 values for the CodTHC codrug were much lower in tail flick and CCI models as compared to codeine. CodCBD codrug was also analysed for its analgesic effect using tail-flick test.

The Cod-THC codrug was initially evaluated for its stability in buffers ranging
from pH 1 to pH 9, as well as in simulated gastric and intestinal fluids (SGF and SIF,
respectively), and in rat plasma and brain homogenate. SGF simulates stomach fluid and
incorporates acidic and enzymatic hydrolysis conditions. SIF mimics the intestinal
enzymes. The stability of the codrug was determined in the following media utilizing an
HPLC-UV assay.
•

pH : Aqueous buffers (37 ºC, pH 1-9)

•

Gastrointestinal tract : Simulated gastric fluid (USP, 37 ºC)

•

Gastrointestinal tract : Simulated intestinal fluid (USP, 37 ºC)

•

Plasma : Rat plasma (37 ºC)

•

Brain homogenate (37 oC)

The codrug was found to have a favorable drug stability profile for oral
administration, being stable in aqueous solutions over a wide range of physiologically
relevant pHs from 1 to 7.4, and was also stable in SGF, SIF and rat brain homogenate. In
rat plasma, the codrug was hydrolyzed to the two parent drugs, codeine and Δ9-THC with
a rate constant of 0.282 hr-1.

Results of the comprehensive stability study of the Cod-THC codrug in different
non-enzymatic aqueous buffers and in biological media demonstrate that the carbonate
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ester linkage of the codrug is predicted to be stable in the gastrointestinal tract when the
codrug is administered orally. Hydrolysis of the carbonate ester linkage in 80% rat
plasma showed that the codrug is enzymatically cleaved to generate the parent durgs,
suggesting that after oral administration, and absorption from the gastrointestinal tract the
codrug will generate both parent drugs in the systemic circulation (plasma). Linker
design in the codrug synthesis has to be carried out in a thoughtful way such that the
linker is not too chemically labile or too stable. Codrugs with labile linkers will not
survive the harsh conditions of the gastrointestinal tract, and thus will hydrolyze in the
gastrointestinal tract before the codrug reaches the systemic circulation. Codrugs with
very stable linkers may reach the systemic circulation, but may not be capable of
generating the parent drugs in the plasma. Thus, the choice of a carbonate ester linkage
linking the allylic hydroxyl group of codeine and the phenolic group of Δ9-THC was
found to be an ideal codrug linker design for oral administration. The stability of the CodΔ9-THC codrug in rat brain homogenate indicates that the enzymes present in rat brain
homogenate are incapable of cleaving the codrug into the parent drugs. Therefore, this
study predicts that any codrug entering the brain from the systemic circulation will not be
transformed into the parent drugs. Thus, if oral administration of the codrug to rats results
in the presence of the parent drug molecules in brain, then these parent drugs must have
entered the brain as the individual parent drug molecules from the systemic circulation,
and did not originate through hydrolysis of the codrug in the brain.

The pharmacokinetic profile of the Cod-THC codrug was evaluated in the rat after
oral administration and compared with the pharmacokinetic profile of the physical
mixture of the parent drugs Several groups have reported the low bioavailability of THC
(2 to 6%) and codeine (4 to 8%) after oral administration in rats, due to poor absorption
from the gastrointestinal tract (Chiang and Barnett, 1984; Shah and Mason, 1990).
Therefore, rat plasma and brain concentrations, of the Cod-THC codrug were determined
after oral and i.v. administration utilizing an LC-MS/MS analytical methodology.These
properties were compared with those obtained after oral administration of an equimolar
physical mixture of the two parent drugs, codeine and Δ9-THC.
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The plasma concentrations of codeine and Δ9-THC were found to be much higher
after oral administration of the codrug in the rat, compared to plasma concentrations of
these drugs after oral administration of the equimolar physical mixture of the two parent
drugs. The parent drugs were clearly released from the codrug molecule in 1:1 ratio in
plasma, while administration of the physical mixture did not afford equimolar
concentrations of codeine and Δ9-THC in the plasma. This is likely due to the different
pharmacokinetic profiles of the two parent drugs, and to the different pharmacokinetic
profile of the Cod-THC codrug. Also, the parent drugs were present in plasma for a
longer period of time after oral administration of codrug, probably due to the sustained
release of the parent drugs from the codrug in the plasma. The actual codrug
bioavailability was calculated to be 7.7 ± 3.8 %, and the total codrug bioavailability was
found to be 21.1 ± 7.9 %. Since the total codrug bioavailability is much higher than the
bioavailabilities of either of the parent drugs after oral administration of the physical
mixture, this shows that more of parent drugs can be delivered orally in the form of the
codrug than as a physical mixture. It should be noted that the total codrug bioavailabilty
value may be underestimated, since the clearance parameters are not taken into account
for the parent drug. But still, the data clearly indicates the superior pharmacokinetic
profile of a codrug as compared to the physical mixture of the two parent drugs.

The time versus concentration profiles for the Cod-THC codrug and the
equimolar physical mixture were generated to determine the concentrations of the parent
drugs in the brainafter oral administration. The Cod-THC codrug was not detected in the
brain, which indicates that the hydrolysis of the codrug is taking place in the plasma, and
then the parent drugs cross the blood-brain-barrier to exert their effect. The
concentrations of codeine and Δ9-THC were much higher in brain after oral
administration of the Cod-THC codrug as compared to brain concentrations of these
drugs after oral administration of the physical mixture. The concentrations of codeine and
Δ9-THC in the brain reach a maximum at two hours after oral administration. This
correlates with the study of the codrug in the pain models. The Δ9-THC concentration
was found to be higher than the codeine concentration in brain after oral administration of
the physical mixture while the concentration of codeine was higher in the brain after oral
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administration of the codrug. This may be attributed to the higher plasma concentration
of Δ9-THC compared to codeine in plasma samples after oral administration of the
physical mixture.
The above data indicate that oral administration of a codeine-Δ9-THC codrug
could be useful therapeutic delivery sssrategy to enhance the pain modulating properties
of codeine. Thus, if extrapolatable to humans, following opioid administration in the
form of an opioid-THC codrug, patients might require a lower dose of opioid, need fewer
administrations of the opioid to control pain, and subsequently experience fewer side
effects. Not only that, in cancer chemotherapy, where opioids show little or no effect in
managing chemotherapeutically-induced neuropathic pain, the codrug approach of
combining an opioid with a THC may be a better substitute for codeine alone, since it
would be effective in managing a broader spectrum of pain.

Thus, this study proves the hypothesis that a codrug of an opiate and a
cannabinoid can be synthesized, which is stable in gastrointestinal tract and shows a
superior pharmacokinetic profile when compared to a physical mixture of the two parent
drugs that make up the codrug. Also, an enhanced pharmacological effect of the codrug
can be achieved compared to that of the two parent drugs.

Copyright © Harpreet Dhooper 2010
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